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CHAPTER - I 
INTRODUCTION  
Nanotechnology can be defined as the science and engineering involved in 
the design, synthesis, characterization and application of materials and devices, 
whose smallest functional organization in atleast one dimension is on the nanometer 
scale (one billionth of a meter). It can prove to be a boon for human health care.  
Because  nano science and nanotechnology have a huge potential to bring benefits in 
areas as diverse as drug development, water decontamination , information and 
communication technologies and production of stronger /lighter materials. Human 
health nanotechnology research can definitely result in immense health benefits. The 
genesis of nanotechnology can be traced to the promise of revolutionary advances 
across medicines, communications, genomics and robotics(SahooS.K. et al., 2007). 
Different types of nano sized carriers, such as polymeric nanoparticles, solid lipid 
nanoparticle , ceramic nanoparticles, magnetic nanoparticles, polymeric micelles, 
polymer-drug conjugates, nanotubes, nanowires, nanocages and dentrimersetc, are 
being developed for various drug delivery (Sahoo S.K. et al., 2008). Polymeric 
nanoparticles can be fabricated from polysaccharides, proteins and synthetic 
polymers. Nanoparticles made from natural hydrophilic polymershave been proved 
efficient interms of better drug loading capacity, bio compatibility and possibly less 
opsonization by reticuloendothelial system through an aqueous steric barrier(Liu Z. 
et al., 2008). 
 
 
CHAPTER – I   INTRODUCTION 
 
CEF BSA NP Reg. No: 261211305 Page 2 
 
Nano antibiotics: 
The bacterial resistance to antimicrobial drugs has been attempted to be 
resolved by discovery of new antibiotics unfortunately there is no assurance . One of 
the recent efforts in addressing this challenge lies in exploring antimicrobial 
nanomaterials, to which microbial pathogens may not be able to develop resistance 
and novel nanosized platforms for efficient antibiotic delivery.Antimicrobial 
nanoparticles offer many distinctive advantages in reducing acute toxicity, 
overcoming resistance and lowering cost when compared to conventional antibiotics. 
Theoretically nanoparticles are retained much longer in the body than small molecule 
antibiotics, which could be beneficial for achieving sustained therapeutic effects. Use 
of nanotechnology in immunization, design and delivery of antimicrobial drugs, 
diagnosis and control of cross infections in particular overcoming antibiotics 
resistant pathogens alternative to the current antibiotics based approaches. 
Nanomaterial, which either show antimicrobial activity by themselves or 
elevate the effectiveness and safety of antibiotics administration, are called “nano 
antibiotics” and their capability of controlling infections invitro and in vivo has been 
explored and demonstrated. 
Recently, antibiotics formulated in polymeric nanoparticles have 
demonstrated enhanced antimicrobial activities and anti MRSA activities, compared 
with non polymerized forms of penicillin and N- methylthio β lactams. A wide range 
of antimicrobial agents can be effectively administered using various nanoparticles. 
Many types of liphophilic and water soluble antibiotics can be conjugated inside or 
on the surface of nanoparticles or carried via encapsulation. Pharmacokinetics 
characteristics of antibiotics, including improved solubility, controlled release and 
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specific site targeted delivery can be achieved by employing appropriate 
nanocarriers.   
 
 
 
 
  
   
 
 
FIGURE (1).VARIUOS ANTIMICROBIAL MECHANISMS OF 
NANOMATERIALS. 
Advantages of nanoantibiotics: 
 They are stable enough for long-term storage with a prolonged 
shelf-life. 
 Controllable and relatively uniform distribution in the target 
tissue. 
 Improved solubility. 
 Sustained and controlled release. 
 Improved patient compliance. 
 Minimized side effects. 
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 Enhanced cellular internalization. 
 Prolonged drug half-life and systemic circulation time. 
 Sustained and stimuli-responsive drug release. 
 Eventually lowers administration frequency and dose. 
(Young Jik Kwon et al., 2011) 
Antimicrobial Polymeric nanoparticles: 
 The first polymer based delivery of macromolecules was demonstrated in 
1976, controlled drug release using biocompatible and biodegradable polymers 
further emerged in the 1980’s and  has been extensively investigated in the clinic for 
enhanced intracellular drug delivery and reduced rapid clearance by 
reticuloendothelial system. 
 There are currently two major types of polymericnanoparticles for 
antimicrobial drug delivery. One is formedvia spontaneous self-assembly of diblock 
copolymers consistingof hydrophilic and hydrophobic segments. The 
hydrophobicsegment forms a polymeric core containing thedrugs while the 
hydrophilic segment shields the core from 
opsonization and degradation. The rate of drug release canbe tuned by varying the 
length of the hydrophobic chain. Avariety of biodegradable polymers have been used 
to formthe hydrophobic polymeric core, including poly(lactic acid)(PLA), 
poly(glycolic acid) (PGA), poly(lactide-co-glycolide)(PLGA), poly (-carprolactone) 
(PCL), and poly(cyanoacrylate) (PCA),whereas polyethylene glycol (PEG) hasbeen 
commonly used as a hydrophilic segment. Diblock copolymernanoparticles are 
typically prepared through solventdisplacement. In this process, polymers and drugs 
are firstdissolved in a water-miscible organic solvent such as acetonitrile.The 
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polymer-drug mixture is then added to an aqueoussolution. As the organic solvent 
evaporates, the blockcopolymers and drugs undergo nanoprecipitation to 
formnanoparticles consisting of a hydrophobic core and a hydrophilicshell. Polymeric 
nanoparticles are primarily used tocarry and deliver poorly water soluble drugs 
because of thehydrophobic nature of the nanoparticle core. 
 The other type of polymeric nanoparticles consists of linearpolymers such as 
polyalkyl acrylates and polymethylmethacrylate that form nanocapsules through an 
emulsionpolymerization method. In this process, monomers are firstdissolved in 
polymerization media in the presence of surfactants.Polymerization initiators are then 
added to the solutionto trigger polymerization resulting in the formation of 
nanocapsules.Antimicrobial drugs can be either absorbed to thenanocapsules during 
the polymerization process or covalentlyconjugated to the surface of the nanoparticles 
afterthey are formed. The absorption process favors hydrophobicdrugs as it requires 
dissolving the drugs to an oil phase. Hydrophilicdrugs are usually attached to the 
particle throughcovalent conjugations. It is worth noting that in the case ofcovalent 
linkage, antimicrobials can be inactivated and needto be verified of their activity 
before use. For instance, in astudy on treating staphylococcal infections, Abeylathet 
al.have observed that β-lactam and ciprofloxacin retained theirpotency whereas 
penicillin was inactivated upon covalentattachment to nanoparticles .Polymeric 
nanoparticles have been explored to deliver avariety of antimicrobial agents to treat 
various infectiousdiseases and have shown great therapeutic efficacy. For example,the 
antimicrobial activity of amphotericin B-loadedpoly(β-caprolactone) nanospheres 
coated with non ionic surfactantpoloxamer 188 have shown greater therapeutic 
efficacyagainst LeishmaniaDonovanihas compared to the freedrug counterparts. 
Rifampicin-loaded polybutylcyanoacrylatenanoparticles have shown enhanced 
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antibacterialactivity both in vitro and in vivo against Staphylococcusaureusand 
Mycobacterium aviumdue to an effective delivery of drugs to macrophages(Zhang L. 
et al., 2010). 
 
 Proteins are class of natural molecules that have unique functionalities and 
potential applications in both biological as well as material fields. Controlled drug 
release and subsequent biodegradation are important for developing successful 
formulations(Karthick Raja NamasivayamS. et al., 2013).  System based on proteins 
including gelatin, collagen, casein, albumin and whey protein have been studied for 
delivering drug, nutrients, bioactive peptides and probiotic organisms. Proteins 
represent good raw materials, since they have the advantages of absorbability and 
low toxicity of the degradation end products. 
Potential release mechanisms involve in protein nanoparticles are 
 Desorption of surface – bound / adsorbed drugs. 
 Diffusion through the carrier matrix. 
 Diffusion through the carrier wall ( in the case of nanocapsules). 
 Carrier matrix erosion/diffusion process. 
(Karthick Raja Namasivayam S. et al., 2013). 
Albumin nanoparticles: 
Among the available potential colloidal drug carrier systems, protein based 
nanoparticles are particularly interesting as they hold certain advantages such as 
greater stability during storage nontoxic, non antigenic and their ease to scale up 
during manufacture over other drug delivery systems. Albumin based nanoparticle 
CHAPTER – I   INTRODUCTION 
 
CEF BSA NP Reg. No: 261211305 Page 7 
 
carrier system represents an attractive strategy, since a significant amount of drug 
can be incorporated into the particle matrix because of the different drug binding 
sites present in the albumin molecules. Due to the defined albumin primary structure 
and high content of charged amino acids. Albumin based nanoparticles could allow 
the electrostatic adsorption of positively or negatively charged molecules without the 
requirement of other compounds. In addition, albumin nanoparticles can be easily 
prepared under soft condition by coacervation, controlled desolvation or emulsion 
formation. They show smaller particle size compared to microparticle, better 
controlled release properties than liposomes which may improve patient acceptance 
and compliance(Ahmed O.Elzoghby et al., 2012). 
Advantages: 
 Albumin is an attractive macromolecular carrier that has been shown to be 
biodegradable, non toxic, metabolized invivo to produce innocuous degradation 
products, non immunogenic, easy to purify and soluble in water, allowing easy of 
delivery by injection. Nanoparticle made of albumin are biodegradable, easy to 
prepare and reproducible. Due to the high protein binding of various drugs, the 
matrix of albumin nanoparticle can be used for effective incorporation of these 
compounds. Covalent derivatization of albumin nanoparticles with drug targeting 
ligands is possible, due to the functional groups on the nanoparticles surface.  
Preparation techniques of albumin nanoparticles 
 Desolvation method ( coacervation) 
 Emulsification method 
 Thermal gelation method 
 Nano spray drying method 
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 Nab – technology ( nanoparticle albumin bound technology) 
 Self assembly method 
Desolvation method: 
In desolvation process, nanoparticles are obtained by continuous dropwise 
addition of ethanol to an aqueous solution of albumin under continuous stirring  until 
the solution became turbid. Then coacervates were hardened by crosslinking with 
glutaraldehyde.er ethanol elimination by evaporation under reduced pressure. 
Prepared nanoparticles were purified by centrifugation to eliminate the free albumin 
and the excess crosslinking agent. The nano suspension was freeze dried using 5% 
mannitol as a cryoprotectant to obtain a fine powder of the nanoparticles. 
Desolvation method is a robust and reproducible method for the denaturation of 
albumin. 
 
FIGURE (2). PREPARATION OF ALBUMIN NANOPARTICLES BY 
DESOLVATION METHOD 
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Emulsification method: 
Emulsification technique has been extensively used for preparation of 
polymeric nanoparticles. Two main methods are used for stabilization of albumin 
nanoparticles, thermal or chemical treatment. Albumin nanospheres of 0.3 - 1µm 
were formed by homogenizing the oil phase containing the albumin droplets at a 
high speed. Then thermally stabilized by heating at 175º to 180ºc for 10 minutes. 
This mixture was cooled and diluted with ethylether to reduce the oil viscosity to 
facilitate separation by centrifugation. In chemical stabilization albumin aqueous 
solution was emulsified in oil at 25ºc then denatured by resuspension in ether 
containing the cross linking agent.  
This technique requires organic solvents for removal of both oily residues 
and surfactants. Furthermore thermal stabilization is applicable only to drug 
molecule that are not heat sensitive. However chemical stabilization, the toxicity of 
the chemical crosslinking agents remain the main problem.   
Thermal gelation: 
Thermal gelation is a sequential process , that involves heat induced 
unfolding followed by protein-protein interactions including hydrogen bonding, 
electrostatic, hydrophobic interactions and disulfide-sulfhydryl interchange reactions. 
Thermal gelation is a successful method to prepare albumin nanoscale hydrogel for 
loading and releasing drugs. 
Self assembly: 
In this method increasing the hydrophobicity of albumin by addition of 
liphophilic drug and diminishment of primary amine groups on protein surface could 
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drive the self assembly of HSA and formation of polymeric micelles. Nanoscale 
micelles prepared in this method can provide high deree of drug loading at the 
hydrophobic core of micelles acts as a micro reservoir for poorly water soluble 
drugs.   
Nano spray drying: 
Spray drying is a well estabilished method commonly used in the 
pharmaceutical industry for preceding a dry powder from a liquid phase. Unlike 
conventional spray dryer, the newnano spray drier utilizes a vibratingmesh 
technology for fine droplets generation. Basically the piezoelectric crystal driven 
spray head is incorporated with a small spray cap that contains a thin perforated 
membrane (spray mesh) having an array of precise micron seized holes. When the 
piezoelectric activation is driven at an ultrasonic frequency (i.e60 KHz), the mesh 
will vibrate upwards and downwards, injecting millions of precisely sized droplets 
from the holes and generating the aerosols. 
In contrasts to common cyclone technology, particle separation in the nano 
spray dryer involves the use of the electrostatic precipitator where by the collection 
mechanism is independent of particle mass. Collection of fine particles with high 
efficiency is achieved with the novel electrostatic particle collector consisting of a 
grounded star electrode (cathode), and cylindrical particle collecting 
electrode(anode). The presence of high voltage around the particle collector creates 
an electrostatic field that accelerates the deposition of negatively charged particles 
onto the inner wall of particle collecting process. This is followed by a discharging 
process (Lee S.H. et al., 2011) 
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FIGURE (3).THE FUNCTIONAL PRINCIPLE OF AN 
ELECTROSTATIC PARTICLE COLLECTOR IN THE NANO SPRAY 
DRYER. 
It has advantage of drying and particle formation in a single step continuous 
and scalable process. 
Nanoparticle albumin bound technology:  
American bio science inc, has developed a unique albumin bound 
nanoparticle technology (nab-technology) that is ideal for encapsulating liphophilic 
drug into nanoparticles. The drug is mixed with HSA in an aqueous solvent and 
passed under high pressure through a jet to form drug albumin nanoparticles in the 
size range of 100-200nm. Several nab drugs are currently under development.(Desai 
N.abraxis bioscience inc, 2007). 
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Nab technology were designed to be safe and suitable for intravenous usage 
of poorly soluble drugs. Albumin bound nanoparticle technology does not require 
surfactants or polymeric materials for preparation. In this method sulfhydryl residues 
of HSA may be oxidized ( and existing disulfide bonds may be disrupted) to form 
new crosslinking disulfide bonds. However, the disulfide formation induced by 
homogenization does not substantially denature the HSA.   
 
FIGURE (4). PREPARATION OF ALBUMIN NANOPARTICLES BY 
NANOPARTICLE ALBUMIN BOUND TECHNOLOGY. 
Surface modified albumin nanoparticles: 
Albumin based nanoparticle offer various possibilities for surface 
modification due to the presence of functional groups (i.e. carboxylic and amino 
group). On the surface of the nanoparticles conjugation of surface modifying ligands 
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is usually achieved through covalent bond formation between the ligands and the 
functional groups of albumin surface. However surface coating or electrostatic 
adsorption techniques may be also utilized for surface modification of the 
nanoparticles. In the albumin – ligand combinations the protein acts as a 
biodegradable carrier for drug delivery where as ligand is used for, 
 Modification of pharmacokinetic parameters (e.g. surfactants) 
 Enhancing the stability  (e.g. poly-L-lysine) 
 Prolonging its circulation (e.g. poly ethylene glycol) 
 Slowing the drug release (e.g. cationic polymer) 
 Targeting agent (e.g. folate, transferrin, apolipoptrotein and           
 monoclonal antibodies) 
(Ahmed O.Elzoghby et al., 2012). 
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CHAPTER – II 
LITERATURE REVIEW 
Abdul HasanSathali.Aet al., 2011, studied to improve the ocular bioavailability 
of levofloxacin and also reducing the frequency of administration. Niosomalinsitu 
gelling system was selected to provide prolonged action by preventing the 
enzymatic metabolism of the drug. Noisomes are formulated by thin film 
hydration method. pH triggered gelling system prepared using polymers such as 
carbopol -940 and HPMC K4M, formulation were evaluated for their clarity, pH, 
antimicrobial activities.  
Ahmed O.Elzoghlyet al., 2012, discussed about albumin nanoparticles with 
respect to types, formulation aspects, major outcomes of invitro and invivo 
investigation, as well as site specific drug targeting using various ligands 
modifying the surface of albumin nanoparticles with special insights to the field of 
oncology. And also discussed about specialized nanotechnological techniques like 
desolvation, emulsification method, thermal gelation, recently nano spray drying, 
nab technology and self assembly method. 
Amit das et al., 2004, investigated the structural changes of bovine serum 
albumin during its unfolding in the presence of urea, a small angle neutron 
scattering study was performed. The scaterring curves of dilute solution of BSA 
with different concentrations of urea in D2O at pH 7.2 ± 0.2 were measured at 
room temperature, scattering profile was fitted to a prolate ellipsoidal shape of the 
protein with a=52.2 Aº and b=24.2 Aº . thedimentions of the protein as it unfold 
was found to be anisotropic. 
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AnkaraoA. et al., 2012, prepared the oral sustained release nanoparticles of 
carvedilol, nanoparticles were prepared by coacervation method using 
ethanolicglutaraldehyde as crosslinking agent. The particle size was ranging from 
500-1000nm, the maximum drug entrapment and yield were about 76.82 and 
76.55 respectively. The sustained release behavior of nanoparticles evaluated both 
acid and phosphate buffer. 
Bigucci F.et al., 2011, fabricated albumin nanoparticles carrying cyclodextrins for 
nasal delivery of tacrine prepared by coacervation method followed by thermal 
crosslinking. The drug was loaded by soaking the prepared nanoparticles in a 
solution of tacrine hydrochloride then lyophilized. Thermal analysis and FTIR 
were performed in order to confirm protein cross linking and possible drug carrier 
interaction. Prepared nanoparticles were evaluated for particle size, zeta potential 
and morphology of surface, as well as drug loading, mucoadhesion properties and 
ex vivo drug permeation ability. 
EspuelasmillanM.S. et al., 2004, evaluated the potential of  albuminnano 
particles as a delivery system for antisense oligonucleotide. Nano particles were 
prepared by a coacervation process and cross-linkage with glutaraldehyde. 
Phosphodiester(PO) and phosphorotiate (PS) oligonucleotide were either adsorbed 
on the surface of  nano particles (PO-NPA and PS-NPA) or incorporated in the 
nano particles matrix (PO-NPB and PS-NPB). The antiviral activity was evaluated 
in MRC-5 fibroblasts infected with human cytomegalovirus at a MOI of 0.0035. 
Both PO nano particles formulation significantly increased the antiviral activity, 
these finding were well correlated with the intracellular distribution observed for 
fluorescent oligonucleotide-loaded albumin nano particles. Albumin nanoparticles 
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partially protected a PO against enzymatic degradation and improved their 
presence in the nucleus. 
Fabio bignottiet al., 1997, prepared surface modified albumin nanospheres with a 
size of around 100nm in diameter from poly(amidoamine)- poly (ethyleneglycol) 
copolymer grafted human serumalbumin and poly(thioetheramido acid) – poly 
(ethylene glycol) copolymer grafted human serum albumin. The nanospheres were 
produced using pH coacervation method and cross linked with glutaraldehyde. 
The cross linking efficiency was affected by the type of albumin conjugate used, 
zeta potentials of the surface modified nanospheres was significantly lower than 
that of unmodified particles, and also reduced plasma protein adsorption on the 
particle surface. 
Frangworeket al., 2011, developed HI6 human serum albumin nano particles to 
deliver variety of drugs across the BBB into the brain. HI6 dimethanesulfonate 
and HI6 dichloro monohydrate were bound to nano particles. At the pH of 8.3 
maximum drugs binding capacity of 344.8 μg and 322.6 μg per mg of nano 
particles were calculated for HI6 dimethanesulfonate and HI6 dicholoro 
monohydrate respectively. Invitro testing of the nano particulate oxime 
formulations in primary porcine capillary endothelial cells demonstrated an upto 
two times higher reactivation of organophosphorus inhibited aceylcholinestrase 
than the free oximes. These finding shows that nano particles made of HSA may 
enable a sufficient antidote for organophosphorus poisoning therapy with HI6 
derivatives even within the central nervous system. 
Guanghui ma et al., 2008, developed thermosensitivepoly(N-iso propyl 
acryamide-co-acrylamine) conjugated albumin nanospheres for thermally 
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targeting the anticancer drugs. Albumin nanoparticles with below 200nm and 
narrow size distribution was successfully prepared in the first step with 
desolvation technique. Then in the second step the  polymer was  conjugated on to 
the surface of the albumin nanoparticles by rdical polymerization. Adriamycin 
was then entrapped into the albumin nanoparticle and polymer conjugated 
albumin nanoparticle(PAN) during the particle preparation. Compared with 
albumin nanoparticle, the drug release from PAN in trypsin solution  was slower. 
Guido baroneet al., 1997, analysed the thermal denaturation process of defatted 
bovine serum albumin. DSC measurements were performed on changing the pH , 
ionic strength and the sodium dodecyl sulphate concentration. Measurements 
shown that the thermal denaturation is always irreversible regardless of pH, ionic 
strength and SDS concentration. The strong stabilizing effect of Nacl on the BSA 
native structure has been found for the range 0-1M, sodium dodecyl sulfate has a 
net stabilizing effect up to a molar ratio of 10:1. 
Hasanuludaget al., 2008, investigated the preparation process of bone 
morphogenetic protein 2 containing bovine serum albumin nanoparticles. The 
nanoparticles were prepared by a coacervation method. Polymer coated 
nanoparticles were characterized with respect to amount of adsorbed polymer , 
particle size and zeta potential. Using bone marrow stromal cells biocompatibility 
of the nanoparticles was investigated by the MTT assay. The size of the 
nanoparticles could be controlled in the range of 50-400nm by process parameters, 
particle size and zeta potentials were increased after coating with cationic 
polymers. 
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Hiroshi saitohet al., 2002, investigated the correlation between invitro 
permeation of 11 β-lactam antibiotics across rat jejunum and their oral 
bioavailability in humans. The absorptive and secretory permeation across the rat 
jejunum was evaluated. A steep sigmoid curve was obtained for the relationship 
between Papp in the absorptive permeation and human oral bioavailability , the 
ratios of  Papp in the absorptive direction to Papp in the secretory direction were 
plotted against human oral bioavailability , a much improved correlation was 
obtained ( r = 0.98 , p<0.001). 
Irache J. M. et al., 2001, studied the invitro drug release properties of the three 
different formulations of gemcitabine loaded albumin nanoparticles prepared by 
coacervation method. Formulation were differentiated depending on the steps 
where the drug and/or cross linking agent added. In all formulation particle size 
ranges between 200-400nm, yield 50%in model A, 65%in model B. nanoparticle 
shows biphasic release profiles. Burst release was especially relevant in model 
A(60%in  1 hour), model B (40%in 1 hour), model C (20% in 1 hour). 
IracheJ.M. et al., 2002, formulated albumin nano particles as carrier for a 
phosphodiester oligonucleotide. Bovine serum albumin nano particles were 
formulated by coacervation process. A phosphodiester oligonucleotide 
incorporated by incubation with the albumin prior to the coacervation process or 
adsorbed onto the prformednano particles. Incorporated and/or adsorbed 
oligonucleotide was estimated by capillary electrophoresis and fluorescence 
spectroscopy. The adsorption  of oligonucleotide was dependent on the pH of the 
medium. Desorption of the oligonucleotide also affected by the pH and ionic 
strength of the medium. Oligonucleotide incubated with the albumin prior to nano 
particle formation , the profile of release confirmed that a fraction was 
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incorporated into the matrix and its release was controlled by the albumin 
degradation. 
Isabelle Migneaultet al., 2004, reviewed glutaraldehyde behavior in aqueous 
solution, reactions with proteins and application to enzyme crosslinking. 
Glutaraldehyde one of the most effective protein crosslinking reagents, it has 
atleast 13 different forms depending on solution conditions such as pH , 
concentration, temperature etc.  Glutaraldehyde  may react with proteins by 
several means such as Aldol condensation or Micheal type addition. 
Glutaraldehyde can react  with several functional groups of protein such as amine, 
thiol, phenol and imidazole because the most reactive aminoacid side-chains are 
nucleophiles. No single mechanism seems to be responsible for 
glutaraldehydecrooslinking with proteins. 
Jahanshahi M.et al., 2008, optimized the formulation of bovine serum albumin  
nanoparticles by applying Taguchi method. Agitation speed, initial BSA 
concentration , pH and temperature were considered as process parametersthe 
result indicates temperature and agitation speed were the most influencing 
parameters on the particle size. The minimum size of nanoparticles (74nm) 
obtained at 4ºc, pH 7.5, 15mg/ml BSA concentration and agitation speed of 
500rpm. 
JahanshahiM. et al., 2006,  fabricated bovine serum albumin nanoparticles, 
several process parameters examined to achieve suitable size. The smallest size of 
nanoparticle was 101nm and the largest size was 503 nm. Agitation speed , 
temperature of the mediumwere the most effective parameters. The minimum size 
of nanoparticlewas obtained at 300-400rpm and 30mg/ml protein concentration. 
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The nanoparticles sample was purified with 50000g centrifugation then followed 
by dialysis, micro and ultra filtration then analyzed. 
Kang Choon Lee et al., 2011, prepared curcumin loaded human serum albumin 
nanoparticles for intravenous administration using albumin bound technology. 
Particle size in the range of 130-150nm, it was investigated by field emission 
scanning electron microscopy and dynamic light scattering and also investigate 
the water solubility of curcumin (300 fold increased). The amount of curcumin in 
tumor after treatment with drug loaded nanoparticles shows 14times higher than 
that of curcumin at 1 hour. 
Kavitaduaet al., 2013, formulated didanosine loaded bsa nanoparticles by 
desolvation techniques, and optimizes the formulation by selecting four process 
variables, stirring speed , pH of the solution , polymer concentration, amount of 
cross linking agent. Nanoparticles prepared at stirring speed 700rpm, pH8.5, 
polymer concentration 60mg/ml and amount of glutaraldehyde 0.6μl/mg of bsa 
was considered as optimized formulation. 
LangerK.  et al., 2003, developed desolvation procedure for the preparation of 
HSA-based nanoparticles between the size range of 100nm-300nm. A pump 
controlledformulation method was established which enabled particle preparation 
under defined conditions. Several factors of the preparation process were 
evaluated. The major factor to determining the particle size is pH of the HSA 
solution, higher  pH leading to smaller particle size, washing the particles by 
differential centrifugation leads to significantly narrowersize distribution. Stability 
of the resulting nanoparticles was evaluated by pH and buffer titration method. 
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Only pH values outside the isoelectric pH range of HSA  and low salt 
concentration were able to prevent nanoparticle agglomeration. 
Langer K.et al., 2008, systematically evaluated excipients for the freeze drying 
and long term stability of albumin based nanoparticles. Empty, doxorubicin 
loaded and PEG-lated nanoparticles were prepared and were freeze dried in the 
presence of different concentration of sucrose, trehalose and mannitol 
respectively. The samples were physicochemically characterized with regard to 
lyophilisate appearance, particle size and polydispersity using photon correlation 
spectroscopy. For evaluation of long term stability samples were stored at 2-8ºc, 
25ºc and 40ºc over predetermined time intervals, particle growth was observed in 
all freeze dried formulations in the absence of cryoprotectants, sucrose and 
trehalose were superior to mannitol. 
Langer K.et al., 2010, studied about specific transport of anticancer drugs into 
tumor cells. Expression of αvβ3 integrins holds promise for anticancer therapy. 
DI17E6 (monoclonal antibody) inhibits growth of melanomas invitro and in vivo, 
also inhibits angiogenesis due to interference with αvβ3 integrins. DI17E6 
covalently coupled to human serum albumin nanoparticles, this nanoparticles 
specifically targeted αvβ3 integrins positive melanomas. 
Langer K.et al., 2000, optimized the desolvation process of Human serum 
albumin for the preparation of  nanoparticles, the resulting nanoparticles were 
stabilized by the addition of varying amount of glutaraldehyde or by heat 
denaturation. The nanoparticles evaluated for particle size, zeta potential, and 
number of amino groups on the surface. The results indicated the particle size 
depends mainly on the amount of desolvating agent added. Increased amount of 
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glutaraldehyde decreases amino groups on the surface of HSA and also the zeta 
potential. Temperature and heat denaturation time influences the stability of HSA 
nanoparticles. 
Langer K.et al., 2007, formulated  doxorubicin loaded HSA nanoparticles  it may 
diminishes the toxicity and optimizes the body distribution of drug, may overcome 
multi drug resistence. Drug was loaded either by adsorption to the nanoparticles 
surface or by incorporation into the particle matrix. Particle size between the 
range of 150nm and 500nm with loading efficiency of 70% to 95%. Cell viability 
ofnanoparticles was investigated in two different neuroblastoma cell lines. 
Anticancer activity of drug loaded nanoparticles were increased in comparison to 
doxorubicin solution. 
Li F.Q.et al., 2008, prepared sodium ferulate loaded albumin nanoparticles by 
desolvation crosslinking method for liver targeting. The nanoparticles were 
spherical in shape, particle size between 100nm and 200nm, charged with zeta 
potential from -20 to -40 mV. Drug entrapment efficiency was decreased along 
with increased amount of glutaraldehyde used for cross linking; invitro drug 
release shows initial burst release and then sustained release. 
Lingdongquanet al., 2013, reviewed, albumin as a drug or imaging agent carrier 
system for rheumatoid arthritis. There are three major types of albumin based 
carrier system for rheumatoid arthritis, including albumin drug conjugates, 
albumin particles and genetic infusion albumin. Their imaging or therapeutic 
effects have been proved in clinical or preclinical studies. The enhanced 
fenestration allows albumin based delivery systems to extravasate at the 
inflammation site. 
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Pedroso T.M et al., 2013, developed UV spectroscopy method validation for 
quantification of cefazolin sodium in pharmaceutical form powder for injectable 
solution. The method presented being capable to detect and quantify the drug , and 
also determined the linear range of concentration, obtaining satisfactory results in 
the linear range of 8 to 28μg/ ml, showing correlation coefficient of 0.9999 when 
analyzed in the wavelength of 270nm. 
Peppas N.A. et al., 2006, reviewed about opsonization ,biodistribution , and 
pharmacokinetics of polymeric nanoparticles. Opsonin  proteins in serum quickly 
bind to conventional non stealth nanoparticles , allowing macrophages of MPS to 
easily recognize and remove these drug delivery devices  before they can perform 
their designed therapeutic function. Pegylation  is one of the method to address 
these limitations, it increases the circulation half life of the nanoparticles. This 
method creates a hydrophilic protective layer around the nanoparticles, blocking 
and delaying the adsorption of opsonin protein via steric repulsion forces. 
Ping yaoet al., 2013, formulated biodegradable doxorubicin loaded bovine serum 
albumin nanoparticles, with folic acid modified dextrin surface by pH adjustment 
and heating process. The nanoparticles have a size about 90nm and excellent 
dispersity at pH 7.4 aqueous solution. The drug loading efficiency is 90%. Anti 
tumor activity of the nanoparticles are evaluated through murine ascites hepatoma 
H22 tumor bearing mice. 
Rintibanerjeeet al., 2012, formulated albumin based nanoparticles for 
ophthalmologic application of aspirin. By varying aspirin albumin ratios from 
0.06 to 1, they obtained, electrokinectically stable, pharmacologically active 
albumin based aspirin nano particles of < 200nm diameter with low 
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polydispersity. Invitro release study showed nanoparticles formulation can release 
aspirin at a sustained rate for prolonged duration (90% at72 hours) and 11% drug 
release in the posterior chamber over a period of 72 hours under simulated 
condition. Stability of the formulation was well maintained on storage for six 
months. The formulation showed no hemolysis in contrast to the free drug. 
Sambadananandanet al., 2013, studied the detailed information about the 
interactions of various drug and nanomaterials with human and bovine serum 
albumin. The interaction was studied by fluorescence spectroscopy due to its high 
sensitivity and straight forwardness. 
SanghoonKoet al., 2011, formulated bovine serum albumin nanoparticles using 
modified desolvation method. Bovine serum albumin nanoparticles and calcium 
loaded bovine serum albumin nanoparticles were fabricated at controlled sizes of 
100nm, 400nm, 800nm. Particle size and surface area to volume ratios of the 
prepared bsa nanoparticles were measured, and it controlled by adjusting bsa 
concentration, pH, sodium chloride content wich affects the coagulation of the bsa 
molecules. 
Sanjudhawanet al., 2011, prepared bovine serum albumin nanoparticles loaded 
with paclitaxel using desolvation technique. A 32 full factorial design was 
employed to formulate nanoparticles. Response surface linear modeling was used 
to predict the optimal formulation. Various models were applied to determine the 
release mechanism. 
Satyaprakashet al., 2010, developed noscopine loaded human serum albumin 
nanoparticles for targeted drug delivery to tumor cells by enhancing the drugs 
bioavailability , distribution and reducing the body’s response towards drug 
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resistance. The nanoparticles were designed and optimized to achieve a particle 
size in the range of 150 – 300 nm with a drug loading efficiency of 85-96%. 
Seyedabbasshojaosadatiet al., 2008, prepared 5-fluorouracil loaded bovine 
serum albumin nanoparticles by phase separation method. Drug release was 
tracked by continuous flow dialysis method. Process variables was optimized by 
through taghuchi’s M16 design. Optimum condition wass found to be 2mg/ml of 
fluorouracil, 3.7ml of ethanol, 176µg of gluaraldehyde, drug protein incubation 
time 30minutes and pH of 8.4, mean diameter were 210nm and zeta potential of -
31.7mV. 
VijayarajkumarP. et al., 2007, prepared HSA – pectin nano particles loaded with 
ciprofloxacin by coacervation method, pectin used to suppress the agglomeration 
of ciprofloxacin loaded human serum albumin nano particles. Various 
physicochemical parameters  were evaluated , size was found to be 180-
290nm.the critical flocculation concentration of nano particles in Na2so4 solution 
was increased from 0.3-0.9M , isoelectric points of the nano particles were found 
to be relatively lower between pH values 3 and 6. 
Wilson B.et al., 2012, formulated and evaluated nanoparticles based on albumin 
to deliver 5-fluorouracil, prepared by coacervation method. The drug loading 
capacity varied from 4.22% to 19.8% w/w, mean particle size was 141.9nm, and 
surface charge was -30.3mV. nanoparticles loaded with drug exerted biphasic 
release pattern with initial burst release followed by sustained release  in pH 7.4 
phosphate buffer. 
Xian-Jun yuet al., 2009, optimized the formulation methods for loading 
gemcitabine into albumin nanoparticles for extended blood circulation and 
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improved efficacy. Two sizes of nanoparticles were prepared by desolvation 
method, with mean diameter of 109.7nm and 405.6nm. The drug loaded by co-
precipitation and follow up adsorption method. Antitumor activity assed by using 
MTT assay. The two nanoparticles possessed smooth surfaces and high drug 
loading efficiency 11% , 13% drug loading respectively. 
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CHAPTER – III 
AIM OF WORK 
  At present cardiac diseases are the major cause of mortality, morbidity 
and disability. Systemic administration of drugs does not provide appropriate 
therapeutic drug levels in the target arteries for sufficient periods of time. Biomedical 
engineers have already succeeded in developing microscale instruments to open 
blocked arteries and to treat other cardiovascular diseases. However these tools are 
bulky, infection prone, and subject to other disorders. The main reason for the failure 
of drugs in clinical trials is the inefficacy of such an approach in providing therapeutic 
drug levels in the target tissues for a sustained period of time. Nanoparticles based 
localized drug therapy using sustained release drug delivery systems could be more 
effective, because it can provide higher and prolonged therapeutic drug level. 
  Nanotechnology explores particles between 1 and 100nm in diameter, 
the size of the individual particles for drug delivery of therapeutic and imaging agents 
may range from 2 to 1000nm. It has been confirmed that particles larger than 200nm 
can activate the human complement system and be cleared from the blood by kupffer 
cells. Additionally splenic filtration captures particles that exceed 200-250nm liver 
filtration captures particles greater than 150nm. For the above reasons current 
research ofnanopharmaceutical formulations focuses on particles less than 200nm. 
(Bawarski W.E. et al., 2008) 
  Cefazolin sodium is classified as a first generation cephalosporin for 
injectable use, it is distinguished by its effectiveness as a therapeutic agent and 
surgical prophylaxis. Cefazolin sodium have significant activity against gram positive 
and gram negative bacteria by inhibiting synthesis of bacterial cell wall in manner 
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similar to penicillins. It has half life of 2 hours and administered every 6 hourly 
during infective endocarditis and requires 1- 1.5gm dosage upto 12gm daily has been 
used. 
 The aim of the present work is to develop and characterizecefazolin sodium 
loaded bovine serum albumin nanoparticles with controlled particle size (< 
200nm)using coacervation method. The controlled particle size is achieved by varying 
the process parameters like pH of the aqueous solution, polymer concentration and 
rpm of the magnetic stirrer. The best formulation is selected based on particle size, 
entrapment efficiency and invitro drug release. Best formulation is further subjected 
to evaluation of particle shape, stability test,infra red spectroscopy and 
microbiological assay.  
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CHAPTER - IV 
PLAN OF WORK 
I. STANDARD CURVES FOR CEFAZOLIN   
a. Preparation phosphate buffer saline pH 7.4. 
b. Estimation of absorption maximum. 
c. Preparation of standard curve of cefazolin. 
 
II. DRUG –POLYMER INTERACTION STUDIES: 
a. Infrared spectroscopic analysis 
 
III. FORMULATION OF CEFAZOLIN LOADED BOVINE SERUM 
ALBUMIN      NANOPARTICLE. 
IV. CHARACTERIZATION OF CEFAZOLIN LOADED BOVINE SERUM 
ALBUMIN  NANOPARTICLE 
a. Determination of drug content. 
b. Determination of drug entrapment efficiency. 
c. Determination of particle size, polydispersityIndex & zeta potential.                      
d. Invitro release studies of cefazolin loaded bovine serum albumin 
nanoparticle using dialysis membrane. 
e. Kinetics of drug release.  
V. SELECTION AND EVALUATION OF BEST FORMULATION. 
a. Infrared Spectroscopic analysis. 
b. Scanning Electron Microscopy analysis. 
c. Microbiological assay. 
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CHAPTER-V 
MATERIALS AND EQUIPMENTS 
 
MATERIALS USED 
1. Cefazolinsodium   - Hospira health care Private Ltd, 
      Chennai. 
2. Bovine serum albumin  -  Hi Media laboratories, Mumbai. 
3. Ethanol    - Changshuyangyuan chemicals, 
      China. 
4. Glutaraldehyde   -  Central Drug House (p) Ltd, 
       New delhi. 
5. Sodium hydroxide   -  Central Drug House (p) Ltd,  
      New delhi. 
6. Sodium chloride   -  RFCL limited, New delhi. 
7. Potassium di hydrogen phosphate -  High purity laboratory chemicals 
      (p) Ltd,Mumbai.  
8. Di sodium hydrogen phosphate -  Nice chemicals (p) Ltd, Cochin. 
9. Trypsine    -  Hi media laboratories (p) Ltd, 
      Mumbai. 
 
 
 
 
 
CHAPTER – V  MATERIALS AND EQUIPMENTS 
 
CEF BSA NP  Reg. No: 261211305 Page 31 
   
 
 
 
EQUIPMENTS USED 
1. Electronic Weighing balance  - A&D company, Japan. 
2. UV-Visible spectrophotometer - Shimadzu corporation, Japan. 
3. Infra red Spectroscopy  -  Shimadzu, Japan. 
4. pH meter     -  M.C.Dalal, India. 
5. Magnetic stirrer   - Remi 1ML, India. 
6. Lyophilizerr    - M.C.Dalal, India. 
7. Refrigerator    -  Kelvinator, India. 
8. Cooling Centrifuge apparatus  - Eppendorf centrifuge 5417R,  
      Germany. 
9. Particle size analyser   - Nano ZS90, Malvern Instruments 
      Ltd, UK. 
10. Scanning electron microscope - Hitachi X650, Tokyo, Japan. 
11. Ultra sonicator   - Vibronic’s ultrasonic processor, 
      India. 
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CHAPTER - VI 
DRUG PROFILES 
DRUG NAME:Cefazolin 
SYNONYMS:cefazolina ,cefazolinum , sefazolin, cephazolin. 
(Martindale The complete drug reference, 36th edition, page 222) 
STRUCTURE: 
 
  
CHEMICAL FORMULA: 
C14H13N8NaO4S3 
IUPAC NAME: 
5-thia-azabicyclo oct-2-ene-2-carboxylic acid, 3-[[(5-methyl-1, 3, 4, 
thiadiazol-2-yl)thio] methyl] -8- oxo -7- [[(1H-tetrazol-1-yl) acetyl] amino] - 
mono sodium salt. 
DESCRIPTION: 
 Nature   : White to off white, very hygroscopic powder. 
 Solubility   : Freely soluble in water, very slightly soluble in  
    alcohol. 
 Molecular weight  : 476.5 gm 
 Melting point   : 190ºc  
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MECHANISM OF ACTION:    
Cefazolin interfere with the synthesis of bacterial cell wall. The bacteria synthesize 
UDP-N-acetylmuramic acid pentapeptide and UDP-N- acetylglucosamine. The 
peptidoglycan residues are linked together forming long strands and UDP is split off. 
The final step is cleavage of the terminal-alanine of the peptide chains by 
transpeptidases; the energy so released is utilized for establishment of linkages 
between peptide chains of the  nieghbouring strands. This cross linking provides 
stability and rigidity to the cell wall. Cefazolin inhibit the transpeptidases so that cross 
linking does not take place. (Ancef GSK) 
PHARMACOKINETICS: 
 Absorption:  
  Not appreciably absorbed from GI tract; must be administered 
parenterally 
 Volume of distribution: 
Widely distributed into tissues and fluids,a including synovial fluid. 
Only low concentrations distribute into CSF. Crosses the placenta and is 
distributed into milk. 
 Metabolism: 
 Not metabolized  
 Excretion: 
Excreted unchanged in urine. Approximately 60% of a dose excreted 
within 6 hours, and 70%-80% excreted within 24 hours in those with normal 
renal impairment. 
 Protein binding:  
74 % - 86% 
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Half-life: 
Serum half-life approximately 1.8 hours after IV administration and 2 
hours after IM administration. 
(www.drugs.com) 
INDICATION: 
Cefazolin mainly used to treat bacterial infections of the skin. It can 
also be used to treat bacterial infections involving the lung, bone, joint , 
stomach , blood, heart valve and urinary tract infection. It is clinically 
effective against infections caused by staphylococci and streptococci species 
of gram positive bacteria.May be used for surgical prophylaxis. 
DOSAGE FORM : 
 Powder for injection IM 1gm/vial. 
 Powder for injection IV 1gm/vial. 
DOSE : 
 Mild infection caused by gram positive bacteria 250-500mg every 8 hours, 
IV/IM. 
 Moderate to severe infections 500mg – 1gm every 6-8 hours, IV/IM. 
 Severe , life- threatening infections 1-1.5gm every 6 hours, IV/IM. 
 Endocarditis, 1-1.5gm every 6 hours, IV/IM. 
 Respiratory tract infections 500mg every 12hours, IV/IM. 
 Septicemia, 1-1.5gm every 6 hours, IV/IM. 
ADVERSE EFFECT : 
 Steven – Johnson syndrome. 
 Hypoprothrombinaemia. 
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 Hypersensitivity reactions. 
 Platelet dysfunction. 
DRUG INTERACTIONS: 
 Aminoglycoside antibiotics – increase the risk of nephrotoxicity. 
 Probenecid – may increase the serum level of  cefazolin. 
CONTRAINDICATIONS: 
Premixed injection (frozen) containing cefazolin in dextrose injection may be 
contraindicated in patients with known allergy to corn or corn products. 
 (AHFS Drug Information) 
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CHAPTER – VII 
EXCIPIENTS PROFILES 
ALBUMIN 
Synonym  : Albumin fraction V, Bovine albumin,Cohn Fraction V 
Chemical name : Serum albumin 
Structure   : It comprises three homologous domains that assemble to form 
a heart shaped molecule, each domain in turn consisting of two sub domainsthat 
possess common structural motify(Guido barone et al., 1997).  
 
 
Description   :  Bovine serum albumin is a single polypeptide chain 
consisting of about 582 amino acid residues and its sequency contains 17 disulfide 
bridges and 1 free cysteine in position 34(Guido barone et al., 1997). 
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Properties   :  
   Appearance – White to yellow with tan to green cast powder. 
   Solubility - Clear to slightly hazy faint yellow to yellow green 
     solution. 
Molecular Weight : 66kDa (SambandamAnandan et al., 2013) 
Functional category : stabilizing agent, therapeutic agent. 
Stability and storage: albumin is a protein and is therefore susceptible to chemical 
degradation     and denaturation by exposure to extremes of 
pH, high salt concentration, heat, enzymes, organic solvents 
and other chemical agents. 
Regulatory acceptance: Included in the FDA inactive ingredients guide. 
 Included in parenteral products licensed in UK. 
    Included in the Canadian list of acceptable non-medical  
   ingredients. 
(Handbook of pharmaceutical excipients edited by Raymond C Rowe et al., sixth 
edition) 
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GLUTARALDEHYDE 
Synonym  : Glutaricdialdehyde, glutaral, pentane 1,5- dial , glutarol ,  
   cidax , sonacide , glutardialdehyde. 
Molecular formula : C5H8O2 
Structure   : 
      
Iupac name  :  Pentanedial.   
Description   :  Glutaraldehyde has fairly small molecules, each with two 
   aldehyde groups (John A. Kiernan, 2000). 
Properties   :  
   Appearance          -   Colorless liquid. 
   Odour           -   pungent. 
   Solubility          -    water, benzene, ether, ethanol. 
   Melting point           -     -15ºc (25% solution). 
   Density                    -    1.06g/ml ( at 20ºc). 
   Boiling point          -     100ºc. 
   Storage temperature -     2º-8ºc. 
(www.chemicalbook.com& www.chemicalindustry.com) 
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Molecular Weight : 100.1g 
Use    : Stabilizing agent, disinfectant, bi functional cross linking  
     agent, electron microscopic fixative agent. 
Stability and storage:  Purified samples of 25% glutaraldehyde stored at -20ºc 
showed virtually no change in their UV absorbance 
characteristic even after 8 months. However solutions are 
very heat sensitive (sigma aldrich MSDS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C
S
C
C
E
F
A
C
EF BSA NP
ynonyms: 
 Cordy
 Mann
 D-Ma
 Pearli
hemical Na
D-Ma
hemical str
 
mpirical Fo
C6H14
unctional C
 Diluen
 Sweet
 Tonic
 Cryop
pplication i
 Mann
 It is u
HAPTER –
  Reg. No: 2
cepic acid. 
a sugar. 
nnite. 
tol. 
me: 
nnitol. 
ucture: 
rmula and
O6 & 182.17
ategory: 
t. 
ening agent
ity agent. 
rotectant. 
n Pharmac
itol is widely
sed as diluen
 VII 
61211305
 
 Molecular 
 
. 
eutical For
 used in ph
ts (10–90%
 E
MANNIT
Weight: 
 
mulation: 
armaceutica
 w/w) in tab
XCIPIENT
OL 
l formulatio
let formulat
S PROFILE
ns and food
ions. 
S 
Page 4
 products.  
0
CHAPTER – VII   EXCIPIENTS PROFILES 
 
CEF BSA NP  Reg. No: 261211305 Page 41 
 
 Mannitol is commonly used as an excipient in the manufacture of chewable 
tablet formulations. 
 Plasticizer in soft-gelatin capsules, as a component of sustained-release tablet 
formulation. 
 It is used as a carrier in dry powder inhalers. 
 It is also used as diluents in rapidly dispersing oral dosage forms. 
 It is used in food applications as a bulking agent. 
Description: 
 Mannitol is a white, odorless, crystalline powder, or free-flowing granules. 
 It has a sweet taste. 
 Microscopically, it appears as orthorhombic needles when crystallized from 
alcohol. 
 Mannitol shows polymorphism.  
Pharmacopoeial Specifications: 
 Density (bulk):0.430 g/cm3. 
 Density (tapped):0.734 g/cm3. 
 Density (true): 1.514 g/cm3. 
 Dissociation constant: pKa = 13.5 at 188C. 
 Flowability: powder is cohesive, granules are free flowing. 
 Melting point: 166–168oC. 
 Loss on drying:  40.3%. 
Stability and Storage Conditions: 
It should be stored in a well-closed container in a cool, dry place. 
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Incompatibilities: 
 Mannitol solutions, 20% w/v or stronger, may be salted out by potassium 
chloride or sodium chloride. 
 Mannitol is incompatible with xylitol infusion and may form complexes with 
some metals such as aluminum, copper, and iron. 
 Reducing sugar impurities in mannitol have been implicated in the oxidative 
degradation of a peptide in a lyophilized formation.  
Handling Precautions: 
Mannitol may be irritant to the eyes; eye protection is recommended. 
(Hand book of Pharmaceutical excipients by Raymond C Rowe -5theditions, 
449-453). 
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CHAPTER - VIII 
EXPERIMENTAL PROTOCAL 
 
I. STANDARD CURVEFOR CEFAZOLIN SODIUM. 
 
a. Preparation of calibration medium (European Pharmacopoeia 2005): 
  Dissolve 2.38gm of disodium hydrogen phosphate, 0.91 gm of 
potassium di hydrogen phosphate and 8gm of sodium chloride in sufficient water to 
produce 1000ml.  
b. Estimation of  absorption maximum for cefazolin: 
       A known weight (100 mg) of drug (cefazolin) is dissolved in 100ml of 
water to make a primary stock solution (1000µg/ml). The stock solution is further 
diluted using a phosphate buffer salinepH (7.4)to produce 10µg/ ml concentration. 
The resultant solution is scanned in the range of (200-400nm) by UV 
Spectrophotometer(UV-1700 Shimadzu corporation, Japan) to get absorption 
maximum(λ max). 
c. Preparation of standard curve: 
 The above prepared stock solution is further diluted with phosphate buffer 
saline pH7.4 to obtain a series of solution in theconcentration range of 5 to 25μg/ml. 
The absorbances of the solutions are measured at λmax 272nm by UV-
spectrophotometer. A standard curves plotted using concentration on x-axis and the 
absorbance obtained on y-axis. 
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II. DRUG POLYMER INTERACTION 
a. Infrared spectroscopic analysis: 
 Infrared spectrum analysis of drug (cefazolin), polymer and the physical 
mixtures of drug with polymers are obtained from FTIR spectrophotometer by KBr 
pellet method. The samples for FTIR analysis is prepared by grinding 99% KBr with 
1% samples and then pressing the mixture into a transparent pellet.The prepared pellet 
is scan at the range (450– 5000cm-1).The spectra obtained are compared and 
interpreted for the shifting of functional peaks or the appearance and disappearance of 
new functional peaks.(Jahanshahi M., et al., 2008). 
III. FORMULATION OF CEFAZOLIN LOADED BSA 
NANOPARTICLES. 
 Cefazolin loaded nanoparticles are prepared by desolvationmethod /simple 
coacervation method.(LangerK. et al., 2003: WilsonB. et al., 2012) 
 Cefazolin (50mg), BSA (100 mg, 200mgand 300mg) are dissolved in 10ml of 
purified water. Then the solution pH is adjusted to pH 8-10. Add ethanol (1:2) 
carefully at a rate of 1ml/min under magnetic stirring. The nanoparticles are cross 
linked by adding 1.56μg of  25% glutaraldehyde(EspuelasMillan M.S., et al.,2004; 
IracheJ.M. et al., 2002) per milligram of bovine serum albumin and stirring continue 
for 3 hours. The nanoparticles suspension is subjected to freeze drying to obtain free 
flowing particles. The plain nanoparticles are prepared by the same procedure without 
drug. 
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IV. CHARACTERIZATION OF CEFAZOLIN LOADED BSA 
NANOPARTICLES. 
 The prepared Cefazolin loaded bovine serum albumin nanoparticles are 
evaluated in terms of drug content, entrapment efficiency, particle size and 
polydispersity index, zetapotential measurement, in vitro drug release studies and 
kinetics of drug release. 
a. Drug content: 
 The total amount of drug content present in the formulation is determined 
using UV spectrophotometric analysis. Nanoparticles equivalent to 2.5mg of cefazolin 
sodium is taken in a 25ml standard flask. To this add 0.5ml of trypsin 1% solution, 
then make up to volume using phosphate buffer saline pH 7.4 and incubated for 24 
hours. From this 1ml is withdrawn and suitably diluted to 10ml using buffer solution. 
The absorbance of the above prepared solution is examined at 272nm by UV 
spectrophotometer. The total drug content can be calculated from the standard curve 
using the formula 
      Sample absorbance 
%drug content =--------------------------------------   X 100 
   Standard absorbance 
(Kavitadua et al., 2013) 
b. Determination  of   Entrapment efficiency: 
                 The amounts of cefazolin sodium encapsulated in the   nanoparticles 
(entrapped drug) areseparated by ultracentrifugation (Eppendorf Centrifuge, 5417R, 
Germany) at 14,000 rpm for 90 min at 4˚C. Then, the sample is taken from the 
separated supernatant liquid and diluted suitably using  the  buffer solution and the 
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amount of  free  drug  present  is  determined  by  measuring  the  absorbance  at  
272nm  by UV- spectrophotometer. The amount of cefazolin sodium encapsulated in 
polymeric nanoparticle formulation is   calculated from the difference between the 
total drug content and the amount of unentrapped drug remaining in the aqueous 
medium. The entrapment efficiency (EE) can be calculated as follows  
 Drug content – unentrapped drug 
Entrapment efficiency =   --------------------------------------------------- x 100 
Drug content 
(RintiBanerjee  et al., 2012) 
 
c. Determination of particle size and zetapotential: 
 The particle size, polydispersity index and zeta potential of 
drug loaded HSA nanoparticles are studied by photon correlation spectroscopy using 
Malvern zeta sizer 3000 (WilsonB. et al., 2012; Langer K. et al 2010). The zeta 
potential is measured with the same instrument by micro electrophoresisusing dip cell 
(Dad pariorM. et al., 2011;Langer K. et al., 2007). Prior to both measurements the 
samples are diluted with distilled water and measured at 25ºc with a scattering angle 
of 90º (Irache J.M. et al., 2001). 
d. Invitro drug release studies: 
 The invitro drug release studies are carried out by using 
dialysis membrane (Li F.Q. et al., 2008; Ping yao et al., 2013). Nanoparticle 
equivalent to 2mg of drug is placed in a dialysis bag (cut off 5K Da). The dialysis bag 
is sealed at both ends then placed in 200ml ofphosphate buffer saline pH 
7.4(dissolution medium). The dissolution medium is stirred continuously at 100 rpm 
and maintain at 37±1ºc. Withdrawn 5ml of dissolution medium at regular time 
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interval and same volume replaced with fresh dissolution medium. The absorbance of 
the samples is measured UV spectrophotometrically at a wavelength of 272nm against 
blank (Wilson B. et al., 2012;Fude Cui et al., 2007). 
e. Kinetics of drug release: 
 In order to investigate the drug release mechanism from bovine serum 
albumin nano particles, the percentagecumulative drug release data is analyzed with 
following mathematical model. 
• Zero-order 
• First order 
• Higuchi 
• Hixson-Crowell cube root law 
• Korsmeyer-peppas model. 
• The zero order rate Equation describes the systems where the drug release 
rate is independent of itsconcentration (no equilibrium concentration are obtained). 
Qt = Q0 + K0t 
 Where,Qt is the amount of drug dissolved in time t,Q0 is the initial amount of 
drug in the solution (mosttimes, Q0= 0) and K0 is the zero order release 
constantexpressed in units of concentration/time.To study the release kinetics, data 
obtainedfrom in vitro drug release studies are plotted ascumulative amount of drug 
released versus time 
•The first order Equation describes the release from a system where the 
release rateis concentration dependent. 
log C = log C0–kt / 2.303    
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Where C is the concentration of the drug at time (t), C0 is the initial 
concentration of the drugand k is the first-order release rate constant.Thedata obtained 
are plotted as log cumulative percentageof drug remaining vs. time. 
• Higuchi describes the drug release as a diffusion process based on fick’s 
law, square root time dependent. 
    Q = kt1/2 
Where Q is the amount of drug released in time t.k is the higuchi dissolution 
constant. This model is based on the hypotheses that (i) initialdrug concentration in 
the matrix is much higher thandrug solubility; (ii) drug diffusion takes place onlyin 
one dimension (edge effect must be negligible);(iii) drug particles are much smaller 
than systemthickness; (iv) matrix swelling and dissolution arenegligible; (v) drug 
diffusivity is constant; and (vi)perfect sink conditions are always attained in 
therelease environment.The data obtained are plotted as cumulative percentagedrug 
release versus square root of time 
•Hixson and Crowell (1931) recognized that the Particles’ regular area is 
proportional to the cuberoot of its volume. They derived the equation 
W01/3 –Wt1/3 = κ t 
Where W0 is the initial amount of drug in the pharmaceuticaldosage form, Wt 
is the remaining amountof drug in the pharmaceutical dosage form at time tand κ 
(kappa) is a constant incorporating the surface-volumerelation.The equation describes 
therelease from systems where there is a change in surfacearea and diameter of 
particles. Tostudy the release kinetics, data obtained from in vitro drug release studies 
are plotted as cube root ofdrug percentage remaining in matrix versustime. 
•Korsmeyer – Peppasmodel describes the fractionof drug release relates 
exponentially with respect to time. 
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Mt / M∞ = Ktn 
Where Mt/M∞ is a fraction of drug released at timet, k is the release rate constant and 
n is the release exponent.In this model, the value of n characterizes therelease 
mechanism of drug. To study the release kinetics,data obtained from in vitro drug 
release studies areplotted as log cumulative percentage drug releaseversuslog time 
Release exponent (n) 
Drug transport 
mechanism 
Rate as a function of 
time 
0.5 Fickian diffusion t - 0.5 
0.5 < n <1 Anomalous  transport t n – 1 
1 Case II transport Zero order release 
Higher than 1 Super case II transport t n – 1 
 
(Paulo costa & Jose manuelsousalobo, 2001). 
V. SELECTION AND EVALUATION OF BEST FORMULATION. 
 The best formulations are selected based on the results 
obtained from particle size analysis, entrapment efficiency, invitrodrug release 
studies. 
a. Infrared spectroscopic analysis: 
 Infrared spectrum (IR) analysis is carried out for the selected 
best formulation to find out the interactions between the drug and excipients used as 
per the procedure mentioned on drug polymer interactions studies. 
b. Morphology of BSA Nanoparticles by SEM analysis: 
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 The morphology of the nanoparticles are observed using 
scanning electron microscopy.  Before observation, lyophilized particles were 
deposited on aluminum stubs using double faced adhesive and coated with gold 
pallatium under an argon atmosphere using a gold sputter module in a high vacuum 
evaporator. (Bigucci F. et al., 2011; SatyaPrakash et al., 2010; SanghoonKo et al., 
2011). 
c. Microbiological assay: 
 The antimicrobial activity of drug and the albumin 
nanoparticles are analysed on the clinically isolated pathogenic strains of 
Staphylococcus aureus. The bacterial organisms are uniformly spread on to the sterile 
nutrient agar medium with sterile cotton swabs,standard and drug loaded albumin 
nanoparticles of 30μg/ml are poured into separate cups bored into sterile agar medium 
previously seeded with organisms. After allowing diffusion of solution for two hours, 
the plates are incubated for 12-24 hoursat 370C.  The zone of inhibition after 
incubation period is observed and recorded. (Karthick Raja Namasivayam S. et al., 
2013; Abdul HasanSathali A.&Sangeetha T., 2011). 
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CHAPTER - IX 
RESULTS AND DISCUSSION 
I. PREPARATION OF STANDARD CURVE FOR CEFAZOLIN. 
a. Preparation of calibration medium. 
 The calibration medium of phosphate buffer saline pH 7.4 was prepared by 
using European Pharmacopeia (2005). 
b. Estimation of absorption maximum. 
 The absorption maximum (λ max)of cefazolin was estimated by scanning the 
10µg/ml concentration (using phosphate buffer saline pH 7.4) of the drug solution in 
UV-region (200-400nm). The obtained spectrum showed the λ max of 272nm in 
phosphate buffer saline pH 7.4 which was shown in Figure. (5). 
c. Preparation of standard curve of cefazolin. 
 The standard curve of cefazolin was prepared using phosphate buffer saline 
pH 7.4.The absorbance of the solutions (5-25µg/ml) was measured in UV –
spectrophotometer at 272nm. The linear correlation coefficient was obtained and it 
was found to be γ=0.9998. Cefazolin obeys the beer‘s law within the concentration 
range of (5-25µg/ml). The standard curve of cefazolin was shown in Table. 
(1)andFigure. (6). 
II. DRUG –POLYMER INTERACTION STUDIES 
a. Infrared spectroscopic analysis 
 Infra red spectroscopic analysis was performed to check out the compatibility 
between the drug (cefazolin) and bovine serum albumin used in the formulation of 
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nanoparticles. IR spectrum of the drug, polymer and the physical mixture of the drug 
with the polymer was shown in the Figure. (7a-7c). The peaks of pure drug and 
polymer obtained was showed in Tables.(2a&2b)and compared with the spectra of 
physical mixture, showed that there was  shifting of functional peaks of BSA. The 
peak position of amide I band in pure BSA moved from 1652.09cm-1 to 1637.62cm-1, 
amide III band moved from 1242.20cm-1 to 1240.27cm-1. The changes in these peak 
positions indicate that drug may interacted with BSA and causing changes in 
secondary structure (KavitaDua&PiyushTrivedi., 2013). 
III. FORMULATION OF CEFAZOLIN LOADED BOVINE SERUM 
ALBUMIN NANOPARTICLES. 
 The desolvation of albumin with organic solvents followed by crosslinking 
with glutaraldehyde is a commonly used method for the preparation of protein 
nanoparticles (Weber C et al., 2000). 
 Various formulation ( F1 – F18) of  cefazolin were prepared using bovine 
serum albumin at different ratios ( 1:2, 1:4, 1:6) and at different pH range (pH 8, pH 
9, pH 10). The formulations were prepared at two different rpm (1000, 500). The 
various parameters were shown in the Table. (3). 
 While addition of ethanol into the protein solution, bovine serum albumin is 
phase separated as its diminished water solubility. Nanoparticles were then formed 
from the albumin solution with the desolvation function produced by ethanol (Li FQ 
et al., 2008). The morphologically formed albumin nanoparticles not sufficiently 
stabilized could consequently redissolved again after dispersed with water and then 
lack an adjustment in drug release rate(Weber et al., 2000). Bovine serum albumin, 
including 60 amino moieties in lysine residues and 2 arginine moieties in 
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guanidinoside chains, might be solidified by condensation reaction with aldehyde 
group contained reagent. So, cross linking with glutaraldehyde was necessary for 
stabilization of desolvated bovine serum albumin nanoparticles. And the cross linking 
process plays a major role in the stability and drug release of the desolvated bovine 
serum albumin molecules (Irache J.M. et al., 2001). 
 In this work, the cross linking step was attentively performed for a period of 3 
hours with 1.56µg (per mg of BSA) of glutaraldehyde. The further obtained results of 
drug loading and release characteristics for the biodegradable cefazolin loaded bovine 
serum albumin nanoparticles also elucidated the practical cross linking condition. 
IV. CHARACTERIZATION OF CEFAZOLIN LOADED BOVINE SERUM 
ALBUMIN NANOPARTICLES. 
a. Determination of drug content: 
 The drug content for all the formulations were found to be in the range of 
91.56% to 98.18% which was shown in Table.(4).The results indicated that there was 
uniform distribution of drug in all nanoparticle formulation. 
b. Determination of entrapment efficiency 
 The impact of drug-polymer ratio and pH on entrapment efficiency was 
considerably significant .The range of entrapment efficiency of formulations F1-F18 
were 31.58% to 68.72% as shown in Tables.(5a-5f) and Figures.(9). 
i. Effect of drug- polymer ratio 
 The entrapment efficiency of cefazolin loaded bovine serum albumin 
nanoparticles was greatly influenced by the drug-polymer ratio. The results were 
shown in Tables (5a-5g)and Figures (9).   . 
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 Formulations F1-F3 prepared using different ratios of bovine serum albumin 
(1:2 ,1:4, 1:6) at pH 9 , 1000 rpm showed the entrapment efficiency of 56.08%, 
49.92%, 50.47% respectively.  
The entrapment efficiency was increased in the order of F2< F3 <F1.   
 Formulations F4-F6 prepared using different ratios of bovine serum albumin 
(1:2 ,1:4, 1:6) at pH 10 , 1000 rpm showed the entrapment efficiency of 50.75%, 
54.82%, 31.58% respectively.  
The entrapment efficiency was increased in the order of F6 < F4 <F5. 
 Formulations F7-F9 prepared using different ratios of bovine serum albumin 
(1:2 ,1:4, 1:6) at pH 8 , 1000 rpm showed the entrapment efficiency of 67.81%, 
65.30%, 58.30% respectively.  
The entrapment efficiency was increased in the order of F9< F8 <F7. 
 Formulations F10-F12 prepared using different ratios of bovine serum 
albumin (1:2 ,1:4, 1:6) at pH 9 , 500 rpm showed the entrapment efficiency of 
60.74%, 36.61%, 40.68% respectively.  
The entrapment efficiency was increased in the order of F11 < F12 <F10.  
 Formulations F13-F15 prepared using different ratios of bovine serum 
albumin (1:2 ,1:4, 1:6) at pH 10 , 500 rpm showed the entrapment efficiency of 
42.53%,49.52 %,49.38 % respectively.  
The entrapment efficiency was increased in the order of F13 < F15 <F14. 
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 Formulations F16-F18 prepared using different ratios of bovine serum 
albumin (1:2 ,1:4, 1:6) at pH 8, 500 rpm showed the entrapment efficiency of  
47.06%,50.98 %,68.72 % respectively.  
The entrapment efficiency was increased in the order of F16 < F17 <F18.  
 From the above results it was observed nanoparticle formulation F7, F8, F17 
has high entrapment efficiency of 67.81%, 65.30%, 68.72% respectively than other 
formulations. 
 The higher entrapment of the drug would be mainly attributed to the 
desolvated phase transition and desolvation technique of nanoencapsulation. As for 
the matrix drug delivery system, hydrophobic interactions can affect the drug loading 
properties. The hydrophobic tendency of protein particles induced by glutaraldehyde 
might also hinder the encapsulation of the hydrophilic water soluble drug (Li F.Q. et 
al., 2008). 
ii. Effect of pH 
 Bovine serum albumin is a protein with amino group and acid group has 
isoelectric pH of 4.5. Protein was relatively stables in the medium with pH around its 
isoelectric point. The entrapment efficiency of bovine serum albumin nanoparticles 
cross linked with glutaraldehyde might be affected by the pH value of the medium      
(  LiF.Q. et al., 2008). 
 Formulations F1-F3 prepared at pH 9 using different ratios of bovine serum 
albumin (1:2 ,1:4, 1:6), 1000 rpm showed the entrapment efficiency of 56.08%, 
49.92%, 50.47% respectively.  
The entrapment efficiency was increased in the order of F2 < F3 <F1. 
CHAPTER – IX   RESULTS AND DISCUSSION 
 
CEF BSA NP  Reg. No: 261211305 Page 56 
 
 Formulations F4-F6 prepared at pH 10  using different ratios of bovine serum 
albumin (1:2 ,1:4, 1:6), 1000 rpm showed the entrapment efficiency of 50.75%, 
54.82%, 31.58% respectively.  
The entrapment efficiency was increased in the order ofF6 < F4 <F5. 
 Formulations F7-F9 prepared at pH 8  using different ratios of bovine serum 
albumin (1:2 ,1:4, 1:6), 1000 rpm showed the entrapment efficiency of 67.81%, 
65.30%, 58.30% respectively.  
The entrapment efficiency was increased in the order of F9< F8 <F7. 
 Formulations F10-F12 prepared at pH 9  using different ratios of bovine serum 
albumin (1:2 ,1:4, 1:6), 500 rpm showed the entrapment efficiency of 60.74%, 
36.61%, 40.68% respectively.  
The entrapment efficiency was increased in the order of F11 < F12 <F10. 
 Formulations F13-F15 prepared at pH 10  using different ratios of bovine 
serum albumin (1:2 ,1:4, 1:6), 500 rpm showed the entrapment efficiency of 
42.53%,49.52 %,49.38 % respectively.  
The entrapment efficiency was increased in the order of F13 < F15 <F14. 
 Formulations F16-F18 prepared at pH 8 using different ratios of bovine serum 
albumin (1:2 ,1:4, 1:6), 500 rpm showed the entrapment efficiency of  47.06%,50.98 
%,68.72 % respectively.  
The entrapment efficiency was increased in the order of F16 < F17 <F18. 
 From the above results the higher entrapment efficiency was observed at pH 
value 8, further increased in pH values decreased the entrapment efficiency. The 
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decreased entrapment efficiency might be concerned with the accelerated cross 
linking step in alkaline condition (Schiff base formed) (Li FQ et al., 2008). 
c. Determination of  particle size and zeta potential 
 The particle size,polydispersity index and zeta potential of drug (cefazolin) 
loaded bovine serum albumin nanoparticles were studied by photon correlation 
spectroscopy(Wilson B et al., 2012; Langer K et al., 2010). The mean particle 
diameter of all formulation from F1-F18 was found to be in the range of 46.9nm-
345.3nm. 
 The mean particle diameter of cefazolin loaded bovine serum albumin 
nanoparticle was influenced by the drug- polymer ratio, pH and rotation per minutes 
of thestirrer, the results were shown in Tables.(6a-6f)&Figures.(10a-10j). 
i. Effect of drug- polymer ratio 
 The influence of different ratio of polymer on cefazolin loaded bovine serum 
albumin nanoparticles was investigated; the results were shown in Tables.(6a-
6f)&Figures.(10a-10j). 
 Formulations F1-F3 prepared using different  ratio of bovine serum albumin 
(1:2 , 1:4 ,1:6)at pH 9, 1000 rpm showed the particle size of  136.9nm , 232.4nm, 
265.9nm respectively.  
The mean particle diameter was increased in the order of F1<F2<F3.  
 Formulations F4-F6 prepared using different  ratio of bovine serum albumin 
(1:2 , 1:4 ,1:6)at pH 10, 1000 rpm showed the particle size of  192.7nm , 220.1nm, 
240.7nm respectively.  
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The mean particle diameter was increased in the order of F4<F5<F6.  
 Formulations F7-F9 prepared using different  ratio of bovine serum albumin 
(1:2 , 1:4 ,1:6)at pH 8, 1000 rpm showed the particle size of  46.9nm , 252.0nm, 
288.2nm respectively.  
The mean particle diameter was increased in the order of F7<F8<F9.  
 Formulations F10-F12 prepared using different  ratio of bovine serum albumin 
(1:2 , 1:4 ,1:6)at pH 9, 500 rpm showed the particle size of  142.2nm , 316.2nm, 
334.2nm respectively.  
The mean particle diameter was increased in the order of F10<F11<F12.  
 Formulations F13-F15 prepared using different  ratio of bovine serum albumin 
(1:2 , 1:4 ,1:6)at pH 10, 500 rpm showed the particle size of  209nm , 305.9nm, 
309.7nm respectively.  
The mean particle diameter was increased in the order of F13<F14<F15. 
 Formulations F16-F18 prepared using different  ratio of bovine serum albumin 
(1:2 , 1:4 ,1:6)at pH 8, 500 rpm showed the particle size of  49.03nm , 138.3nm, 
345.3nm respectively.  
The mean particle diameter was increased in the order of F16<F17<F18.  
 The particle size of all the formulation increased in the order of  
  1:2<1:4<1:6 
 It was concluded that an increase in polymer concentration increased the 
particle size of cefazolin loaded bovine serum albumin nanoparticles. Because 
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increases in bovine serum albumin increase the chances of coagulation, especially, the 
protein molecule have had more chances to undergo electrostatic and hydrophobic 
interactions. Larger hydrophobic interaction of bovine serum albumin increased the 
coagulation of the molecules and subsequently related in larger particles.(sanghoonko 
et al., 2011). 
ii. Effect of pH on particle size 
 The mean particle diameter of  bovine serum albumin  nanoparticles loaded 
with cefazolin were prepared at three different pH conditions (8,9,10) , using different 
concentration  of polymer(1%,2%,3%) at two different rpm(1000,500). The results 
were shown in Tables.(6a-6f)&Figures.(10a-10j). 
 Formulations F1-F3 prepared at pH 9 using different  ratio of bovine serum 
albumin (1:2 , 1:4 ,1:6), 1000 rpm showed the particle size of  136.9nm , 232.4nm, 
265.9nm respectively.  
The mean particle diameter was increased in the order of F1<F2<F3. 
 Formulations F4-F6 prepared at pH 10 using different  ratio of bovine serum 
albumin (1:2 , 1:4 ,1:6), 1000 rpm showed the particle size of  192.7nm , 220.1nm, 
240.7nm respectively.  
The mean particle diameter was increased in the order of F4<F5<F6. 
 Formulations F7-F9 prepared at pH 8 using different  ratio of bovine serum 
albumin (1:2 , 1:4 ,1:6), 1000 rpm showed the particle size of  46.9nm , 252.0nm, 
288.2nm respectively.  
The mean particle diameter was increased in the order of F7<F8<F9.  
CHAPTER – IX   RESULTS AND DISCUSSION 
 
CEF BSA NP  Reg. No: 261211305 Page 60 
 
 Formulations F10-F12 prepared at pH 9 using different  ratio of bovine serum 
albumin (1:2 , 1:4 ,1:6), 500 rpm showed the particle size of  142.2nm , 316.2nm, 
334.2nm respectively.  
The mean particle diameter was increased in the order of F10<F11<F12.  
 Formulations F13-F15 prepared at pH 10 using different  ratio of bovine 
serum albumin (1:2 , 1:4 ,1:6), 500 rpm showed the particle size of  209nm , 305.9nm, 
309.7nm respectively.  
The mean particle diameter was increased in the order of F13<F14<F15. 
 Formulations F16-F18 prepared at pH 8 using different  ratio of bovine serum 
albumin (1:2 , 1:4 ,1:6), 500 rpm showed the particle size of  49.03nm , 138.3nm, 
345.3nm respectively.  
The mean particle diameter was increased in the order of F16<F17<F18.  
 From the above results it was observed that increase in pH decrease in particle 
size (Langer K et al.,2003). The control of the BSA particle size can be explained by 
their surface charge and surface hydrophobicity. Surface hydrophobicity dictates the 
propensity to bind non-polar amino acid groups to a hydrophobic part of its surface. 
Hydrophobic interactions lead to a coagulations among protein molecules, resulting in 
size increase. Under basic conditions such as pH 10 electrostatic interactions increase 
but hydrophobic interaction decrease. In addition at basic pH hydrogen bonding 
increase results in a decrease in the hydrophobicity. At pH 10 there was a decrease in 
the hydrophobic interactions. This results support our hypothesis with regards to 
controlling hydrophobic interaction as a means for controlling the size of bovine 
serum albumin nanoparticles(SanghoonKoet al., 2011). 
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iii. Effect of rpm 
 The mean particle diameter of  bovine serum albumin  nanoparticles loaded 
with cefazolin were prepared at two different rpm(1000,500), using different 
concentration  of polymer(1%,2%,3%) at three different pH conditions (8,9,10). The 
results were shown in Tables. (6a-6f)&Figures.(10a-10j). 
 Formulations F1-F3 prepared at 1000 rpm using different ratio of bovine 
serum albumin (1:2, 1:4, 1:6) inthe pH 9 showed the particle size of 136.9nm, 
232.4nm, 265.9nm respectively.  
The mean particle diameter was increased in the order of F1<F2<F3. 
 Formulations F4-F6 prepared at 1000 rpm using different ratio of bovine 
serum albumin (1:2, 1:4, 1:6) in thepH 10 showed the particle size of 192.7nm, 
220.1nm, 240.7nm respectively.  
The mean particle diameter was increased in the order of F4<F5<F6. 
 Formulations F7-F9 prepared at1000 rpm using different ratio of bovine serum 
albumin (1:2, 1:4, 1:6) in the pH 8 showed the particle size of 46.9nm, 252.0nm, 
288.2nm respectively.  
The mean particle diameter was increased in the order of F7<F8<F9.  
 Formulations F10-F12 prepared at 500 rpm using different ratio of bovine 
serum albumin (1:2, 1:4, 1:6) in thepH 9 showed the particle size of  142.2nm , 
316.2nm, 334.2nm respectively.  
The mean particle diameter was increased in the order of F10<F11<F12. 
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 Formulations F13-F15 prepared at 500 rpm using different ratio of bovine 
serum albumin (1:2, 1:4, 1:6) in thepH 10 showed the particle size of  209nm , 
305.9nm, 309.7nm respectively.  
The mean particle diameter was increased in the order of F13<F14<F15. 
 Formulations F16-F18 prepared at 500 rpm using different ratio of bovine 
serum albumin (1:2, 1:4, 1:6) in thepH 8 showed the particle size of 49.03nm, 
138.3nm, 345.3nm respectively.  
The mean particle diameter was increased in the order of F16<F17<F18.  
 Formulations (F1-F9) were prepared at 1000rpm showed the mean particle 
diameter in the ranges of 46.9nm to 288.2nm. 
 Further formulations (F10-F18) were prepared at 500rpm showed the mean 
particle diameter in the ranges of 49.03nm to 345.3nm. 
  From the above results it was observed that the formulations F1(pH 9, 
1:2, 1000rpm), F7 (pH8, 1:2, 1000rpm), F10(pH9, 1:2, 500rpm), F16 (pH8, 1:2, 
500rpm), F17 (pH8, 1:4, 500rpm) showed the mean particle diameter of 136.9nm, 
46.9nm, 142.2nm, 49.03nm, 138.3nm respectively. 
 The mean particle diameter of the formulations (F1-F18)were decreased with 
increased rpm (Jahanshahi M et al., 2006). Because at higher rpm distribution of 
desolvating agent (ethanol) occurs uniformly which inhibit aggregate formation 
(Kavitadua, Piyushtrivedi 2013). 
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Polydispersity index 
The most important characterization parameter, also called Polydispersity 
Index (PI)which governs the physical stability of nanoparticles and should be as low 
as possible for the long term stability of nanoparticles.  
a) PI value of 0.1–0.25 indicates a fairly narrow size distribution  
b) PI value greater than 0.5 indicates a very broad distribution  
Polydispersity index values for all the formulations were shown in Tables. 
(6a-6f) and Figure.(12a,12b). 
The polydispersity index of formulations (F1-F9) prepared using different 
ratio of polymer (1:2, 1:4, 1:6) at 1000 rpm in different pH (8, 9,10) was found to be 
in the range of 0.183-0.408. 
The polydispersity index of formulations (F10-F18) prepared using different 
ratio of polymer (1:2, 1:4, 1:6) at 500 rpm in different pH (8, 9,10) was found to be in 
the range of 0.164-0.608.  
It was observed all the formulations haspolydispersity index smaller than 0.5 
which indicated anarrow size distribution except F16 (0.608). 
Zeta potential 
 The stability of a prepared bovine serum albumin nanoparticle formulations 
were measured in terms of zeta potentials. It reflects the electrical potential of 
particles and is influenced by the composition of the particle and the medium in which 
it is dispersed (Jahanshahi M et al., 2008).Greater the surface charge, more repulsion 
between particles, which in turn produce a stables suspension by reducing the neutral 
tendency to aggregate (Wilson B et al., 2012). 
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The zeta potential of formulations (F1-F19) prepared using different ratio of 
polymer (1:2, 1:4, 1:6) at 1000 rpm in different pH (8, 9,10) was found to be in the 
range of (-6.78mV to 2.51mV).  
The zeta potential of formulations (F1-F19) prepared using different ratio of 
polymer (1:2, 1:4, 1:6) at 500 rpm in different pH (8, 9,10) was found to be in the 
range of (-6.36mV to -16.5mV).  
 The results were shown in Tables.(6g, 6h) &Figures. (11a-11i & 12a,12b). 
Nanoparticles with a zeta potential above ±30 mV have been shown to be stables in 
suspension, as the surface charge prevents aggregation of the particles (Jahanshahi M 
et al., 2008). 
 Zeta potential is significantly affected by the amount of protein and cefazolin. 
In the coacervation process,glutaraldehyde and cefazolin (highly protein bound) both 
compete for the amino groups of protein. We fixed the concentration of 
glutaraldehyde at 1.56µg/mg of bovine serum albumin. At this concentration 
sufficient number of amino groups is free for cefazolin binding even after binding of 
all the glutaraldehyde to albumin (Rintibanerjee et al., 2005). 
d. Invitro release studies   
 The invitro release of cefazolin from the albumin nanoparticles was studied by 
the dialysis bag diffusion technique. The release study was performed at phosphate 
buffer saline pH 7.4 for 12 hours. The dialysis bag retained nanoparticles and allow 
the diffusion of the drug immediately into the receptor compartment. The results were 
shown in Tables.(7a-7f) and Figures.(13a-13f). 
 The formulations F1-F3 prepared using different ratio (1:2, 1:4, 1:6) of  bovine 
serum albumin in pH 9 at 1000rpm exhibited an initial burst release of 14.72%, 
CHAPTER – IX   RESULTS AND DISCUSSION 
 
CEF BSA NP  Reg. No: 261211305 Page 65 
 
13.33%, 14.11% at 0.5 hour and  62.41%, 64.05%, 62.52% at 12 hours respectively. 
The cumulative percentage of drug release was decreased in the order of F3>F1>F2. 
 The formulations F4-F6 prepared using different ratio (1:2, 1:4, 1:6) of  bovine 
serum albumin in pH 10 at 1000rpm exhibited an initial burst release of  13.19%, 
11.51%, 15.45% at 0.5 hour and  63.90%, 59.34%, 72.24% at 12 hours respectively. 
The cumulative percentage of drug release was decreased in the order of F6>F4>F5.  
 The formulations F7-F9 prepared using different ratio (1:2, 1:4, 1:6) of  bovine 
serum albumin in pH 8 at 1000rpm exhibited an initial burst release of 6.35%, 
14.30%, 16.68% at 0.5 hour and  46.69%, 56.37%, 61.39% at 12 hours respectively. 
The cumulative percentage of drug release was decreased in the order of F9>F8>F7. 
 The formulations F10-F12  prepared using different ratio (1:2, 1:4, 1:6) of  
bovine serum albumin in pH 9 at 500rpm exhibited an initial burst release of 11.93%, 
19.89%, 15.42% at 0.5 hour and  55.10%, 76.52%, 64.26% at 12 hours respectively. 
The cumulative percentage of drug release was decreased in the order of 
F11>F12>F10. 
 The formulations F13-F15 prepared using different ratio (1:2, 1:4, 1:6) of  
bovine serum albumin in pH 10 at 500rpm exhibited an initial burst release of 
23.10%, 21.28%, 24.22% at 0.5 hour and 78.02%, 70.40%, 70.58% at 12 hours 
respectively. The cumulative percentage of drug release was decreased in the order of 
F13> F15 > F14. 
 The formulations F16-F18 prepared using different ratio (1:2, 1:4, 1:6) of  
bovine serum albumin in pH 8 at 500rpm exhibited an initial burst release of 19.75%, 
13.89%, 16.26% at 0.5 hour and  62.17%, 47.78%, 57.36% at 12 hours respectively. 
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The cumulative percentage of drug release was decreased in the order of F16 > F18 > 
F17.  
 From the above results it was observed that all the formulations showed 
biphasic release. All the formulations showed about 20% of drug release quickly from 
cefazolin loaded bovine serum albumin nanoparticles with the first 0.5 hour and then 
followed by relatively slow release rate. This initial burst release was caused by the 
drug dispersed close to the nanoparticle surface. This part of adsorbed drug could be 
easily desorbed from the outer layer and diffused out (Li FQ et al., 2008). The drug 
incorporated into the inner core of the protein matrix contributed for slow release 
phase (Wilson B et al., 2012) & (Irache J.M et al., 2001). The albumin matrix of the 
nanoparticle is stables during invitro drug release, it was reasonable owing to the 
insolubility of denatured bovine serum albumin (Fude cui et al., 2007) 
e. Kinetics of drug release 
The results obtained from the in vitro release studies were attempted to fit into 
various mathematical models as follows: 
a) Zero order rate kinetics - Cumulative percentage drug release Vs time  
b) First order rate kinetics- Log cumulative percentage drug remaining Vs 
      time  
c) Higuchi classical diffusion model- Cumulative percentage drug release Vs
      square root of time  
d) Hixon Crowell erosion equation- Cube root of percentage drug remaining 
      Vs time  
e) KorsmeyerPeppas exponential equation- Log cumulative percentage drug 
       release Vs log time  
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Various plots of zero order, first order, Higuchi matrix, Korsmeyer - Peppas 
and Hixon – Crowell were shown in Figures.(18a-18f). The regression coefficient (r2) 
and n values were shown inTables.(8a,8b). 
Higuchi describes drug release as a diffusion process based on Fick's law, 
which is square root of time dependent. The amount of drug release from cefazolin 
loaded bovine serum albumin nanoparticle formulations (F1-F18)   showed a linear 
relationship with square root of time. Hence, the drug release rate could be expressed 
by Higuchi diffusion model (r2=0.896 to 0.973). The high correlation coefficients 
were obtained for the first order drug release kinetics for all the formulations ranging 
from (r2 = 0.804to 0.925).   
 Different values of n for cylindrical, spherical and slab of geometrics are 
available in the literature (Costa P, Sousa lobo JM 2001). For spheres, values of 0.5, 
0.5 < n < 1.0, 1.0 and higher than 1.0 are related to Fickian diffusion, anomalous, case 
II transport and super case II transport respectively. According to the data presented in 
the Tables. (8a, 8b) the values of exponent n were within 0.5 which indicated that the 
drug release mechanism followed pure Fickian diffusion. This report was in 
accordance with the earlier studies of Wilson B et al., 2012. 
V. SELECTION AND EVALUATION OF BEST FORMULATION. 
 From the above results F7 was selected as the best formulation showing  
  Particle size   : 46.9nm 
  Entrapment efficiency: 67.81% 
  Invitro drug release  : 46.69% at 12 hours 
  Release kinetics  : closest to higuchi model 
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a. Infra red spectrum analysis 
IR spectrum of the best formulations (F7) was recorded and shown in the Figure.(7d). 
The IR spectrum of pure BSA obtained was compared with the spectra of best 
formulations, showed that there was shifting ofsome functional peak. The peak 
position of amino group in BSA moved from 3418.94cm-1 to 3277.27cm-1 after 
formulation of nanoparticles.This result indicatesthe shifting was due to crosslinking 
of amino groups by glutaraldehyde (KavitaDua&PiyushTrivedi., 2013). 
b. Morphology of polymeric nanoparticles by SEM analysis 
 In order to characterize the morphology of nanoparticle formulations SEM 
analysis was performed. The SEM Photograph of the selected best formulations F7 
(cefazolin + 1% BSA + pH 8) were shown in Figure.(19).The results indicated that 
the nanoparticles are spherical in shape and below 0.5µm in size 
c. Microbiological assay 
 The zone of inhibition measured was compared with that of standard and the 
study indicated that cefazolin retained its antimicrobial efficacy even after formulated 
as nanoparticles Figure.(20)(Abdul HasanSathali A.&Sangeetha T., 2011). The 
antibacterial activity against staphylococcus aureus revealed there was a sharp 
increase in zone of inhibition at increased time period and enhanced zone of inhibition 
was recorded after 24 hours with 36mm.(Karthick Raja Namasivayam S. et al., 2013). 
  
 
 
 
 
 
 
 
 
 
 
                           TABLES & FIGURES 
TABLE 1.CALIBRATION OF CEFAZOLIN SODIUM USING PHOSPHATE 
BUFFER SALINE pH 7.4 
 
  
CONCENTRATION μg/ml ABSORBANCE ± SD 
5 0.132 ± 0.010 
10 0.257 ± 0.003 
15 0.378  ± 0.006 
20 0.496  ± 0.014 
25 0.610  ± 0.012 
  n = 3*      γ = 0.9998 ± 0.0003 
           
   
 
 
 
 
 
 
 
 
 
TABLE 2(a). FT-IR PEAKS OF CEFAZOLIN. 
S.NO CHARACTERISTICS WAVENUMBER 
1 NH stretching Near 3422.8 cm
-1 and 
3295.69 cm-1 
2 C=O (carboxylate) stretching 1761.07 cm-1 
3 C=O (amide) stretching  1668.48 cm
-1 
4 COO- stretching 1599.04 cm
-1 and 
1388.79 cm-1 
5 C-S stretching 2934.79 cm-1 
6 C-N stretching 1238.41 cm
-1, 1183.37 cm-1, 
1104.28 cm-1, 1075.35 cm-1 
7 secondary amide 1541.18 cm-1 
8 CH aliphatic stretching 2934.79 cm-1 
9 C=C aromatic stretching 1599.04 cm
-1, 1541.18 cm-1, 
1491.99 cm-1 
 
 
TABLE 2(b). FT-IR PEAKS OF BOVINE SERUM ALBUMIN. 
S.NO CHARACTERISTICS WAVENUMBER 
1 N-H bending Near 3418.93 cm-1 
2 C=O stretching (amide-I) 1652.09 cm-1 
3 N-H bending C-N stretching (amide-II) 1541.18 cm
-1 
4 N-H bending C-N stretching (amide-III) 1242.20 cm
-1 
5 COO- 1396.58 cm-1 
 
 
TABLE 3.VARIUOS PARAMETERS OF CEFAZOLIN LOADED BOVINE 
SERUM ALBUMIN NANO PARTICLE.  
FORMULATION 
CODE 
DRUG 
POLYMER 
RATIO 
DRUG   
(mg) 
POLYMER 
(mg) RPM pH 
F1 1: 2 50 100 1000 9 
F2 1: 4 50 200 1000 9 
F3 1: 6 50 300 1000 9 
F4 1: 2 50 100 1000 10 
F5 1: 4 50 200 1000 10 
F6 1: 6 50 300 1000 10 
F7 1: 2 50 100 1000 8 
F8 1: 4 50 200 1000 8 
F9 1: 6 50 300 1000 8 
F10 1: 2 50 100 500 9 
F11 1: 4 50 200 500 9 
F12 1: 6 50 300 500 9 
F13 1: 2 50 100 500 10 
F14 1: 4 50 200 500 10 
F15 1: 6 50 300 500 10 
F16 1: 2 50 100 500 8 
F17 1: 4 50 200 500 8 
F18 1: 6 50 300 500 8 
 
 
 
 
 
 
 
 
TABLE 4.DRUG CONTENT OF CEFAZOLIN LOADED BOVINE SERUM 
ALBUMIN NANOPARTICLES. 
S.NO FORMULATION CODE DRUG CONTENT(%)    ± SD 
1 F1 92.99 ± 0.840 
2 F2 96.10 ± 1.375 
3 F3 95.08 ± 0.330 
4 F4 93.78 ± 0.478 
5 F5 91.56 ± 0.399 
6 F6 90.78 ± 0.733 
7 F7 94.68 ± 0.183 
8 F8 96.10 ± 0.420 
9 F9 94.16 ± 0.550 
10 F10 97.80 ± 0.243 
11 F11 96.36 ± 0.242 
12 F12 95.32 ± 0.275 
13 F13 96.78 ± 1.606 
14 F14 95.32 ± 0.159 
15 F15 98.18 ± 0.875 
16 F16 97.92 ± 0.459 
17 F17 96.10 ± 0.840 
18 F18 97.28 ± 0.159 
n = 3* 
 
 
 
TABLE 5a. ENTRAPMENT EFFICIENCY OF CEFAZOLIN SODIUM 
LOADED BSA NANO PARTICLES FORMULATED AT  pH 9, 1000RPM 
 
S.NO FORMULATION CODE 
DRUG : POLYMER 
RATIO 
ENTRAPMENT 
EFFICIENCY(%)    ± 
SD 
1 F1 1:2 56.08 ± 0.762 
2 F2 1:4 49.92 ± 0.622 
3 F3 1:6 50.47 ± 0.344 
n = 3* 
 
 
 
 
TABLE 5b. ENTRAPMENT EFFICIENCY OF CEFAZOLIN SODIUM 
LOADED BSA NANO PARTICLES  FORMULATED AT pH 10, 1000RPM 
 
S.NO FORMULATION CODE 
DRUG : POLYMER 
RATIO 
ENTRAPMENT 
EFFICIENCY(%)    ± 
SD 
1 F4 1:2 50.75 ± 0.266 
2 F5 1:4 54.82 ± 0.461 
3 F6 1:6 31.58 ± 0.805 
n = 3* 
 
 
 
TABLE 5c. ENTRAPMENT EFFICIENCY OF CEFAZOLIN SODIUM 
LOADED BSA NANO PARTICLES FORMULATED AT  pH 8, 1000RPM 
 
S.NO FORMULATION CODE 
DRUG : 
POLYMER RATIO 
ENTRAPMENT 
EFFICIENCY(%)    ± 
SD 
1 F7 1:2 67.81 ± 0.849 
2 F8 1:4 65.30 ± 1.453 
3 F9 1:6 58.30 ± 1.063 
n = 3* 
 
 
 
TABLE 5d. ENTRAPMENT EFFICIENCY OF CEFAZOLIN SODIUM 
LOADED BSA NANO PARTICLES FORMULATED AT  pH 9, 500RPM 
 
S.NO FORMULATION CODE 
DRUG : POLYMER 
RATIO 
ENTRAPMENT 
EFFICIENCY(%)    ± 
SD 
1 F10 1:2 60.74 ± 0.477 
2 F11 1:4 36.61 ± 1.752 
3 F12 1:6 40.68 ± 1.707 
n = 3* 
 
 
 
TABLE 5e. ENTRAPMENT EFFICIENCY OF CEFAZOLIN SODIUM 
LOADED BSA NANO PARTICLES FORMULATED AT  pH 10, 500RPM 
 
S.NO FORMULATION CODE 
DRUG : 
POLYMER RATIO 
ENTRAPMENT 
EFFICIENCY(%)    ± 
SD 
1 F13 1:2 42.53 ± 1.377 
2 F14 1:4 49.52 ± 0.915 
3 F15 1:6 49.38 ± 1.537 
n = 3* 
 
 
 
TABLE 5f. ENTRAPMENT EFFICIENCY OF CEFAZOLIN SODIUM 
LOADED BSA NANO PARTICLES FORMULATED AT  pH 8, 500RPM 
 
S.NO FORMULATION CODE 
DRUG : POLYMER 
RATIO 
ENTRAPMENT 
EFFICIENCY(%)    ± 
SD 
1 F16 1:2 50.98 ± 0.737 
2 F17 1:4 68.72 ± 1.870 
3 F18 1:6 47.06 ± 1.557 
n = 3* 
 
 
 
TABLE 6a. PARTICLE SIZE AND PDI OF CEFAZOLIN LOADED BOVINE 
SERUM ALBUMIN NANOPARTICLES FORMULATED AT pH 9,1000rpm. 
FORMULATION 
CODE 
DRUG : 
POLYMER 
RATIO 
MEAN 
DIAMETER 
(nm) 
PDI 
F 1 1:2 136.9 0.245 
F 2 1:4 288 0.214 
F 3 1:6 390.6 0.408 
 
 
TABLE 6b. PARTICLE SIZE AND PDI OF CEFAZOLIN LOADED BOVINE 
SERUM ALBUMIN NANOPARTICLES FORMULATED AT pH 10,1000rpm. 
FORMULATION 
CODE 
DRUG : 
POLYMER 
RATIO 
MEAN 
DIAMETER 
(nm) 
PDI 
F 4 1:2 309.7 0.302 
F 5 1:4 316.2 0.183 
F 6 1:6 522.9 0.281 
 
 
TABLE 6c. PARTICLE SIZE AND PDI OF CEFAZOLIN LOADED BOVINE 
SERUM ALBUMIN NANOPARTICLES FORMULATED AT pH 8,1000rpm. 
FORMULATION 
CODE 
DRUG : 
POLYMER 
RATIO 
MEAN 
DIAMETER 
(nm) 
PDI 
F 7 1:2 46.9 0.265 
F 8 1:4 232.4 0.239 
F 9 1:6 305.9 0.255 
 
 
TABLE 6d. PARTICLE SIZE AND PDI OF CEFAZOLIN LOADED BOVINE 
SERUM ALBUMIN NANOPARTICLES FORMULATED AT pH 9,500rpm. 
FORMULATION 
CODE 
DRUG : 
POLYMER 
RATIO 
MEAN 
DIAMETER 
(nm) 
PDI 
F 10 1:2 142.2 0.309 
F 11 1:4 345.3 0.213 
F 12 1:6 497.6 0.502 
 
 
TABLE 6e. PARTICLE SIZE AND PDI OF CEFAZOLIN LOADED BOVINE 
SERUM ALBUMIN NANOPARTICLES FORMULATED AT pH 10,500rpm. 
FORMULATION 
CODE 
DRUG : 
POLYMER 
RATIO 
MEAN 
DIAMETER 
(nm) 
PDI 
F 13 1:2 334.2 0.482 
F 14 1:4 485.5 0.164 
F 15 1:6 552.2 0.464 
 
 
TABLE 6f. PARTICLE SIZE AND PDI OF CEFAZOLIN LOADED BOVINE 
SERUM ALBUMIN NANOPARTICLES FORMULATED AT pH 8, 500rpm. 
FORMULATION 
CODE 
DRUG : 
POLYMER 
RATIO 
MEAN 
DIAMETER 
(nm) 
PDI 
F 16 1:2 49.03 0.608 
F 17 1:4 138.3 0.327 
F 18 1:6 363.5 0.379 
 
TABLE 6g. ZETA POTENTIAL OF CEFAZOLIN LOADED BOVINE SERUM 
ALBUMIN NANOPARTICLES FORMULATED AT 1000rpm. 
FORMULATION 
CODE pH 
DRUG : 
POLYMER 
RATIO 
ZETA 
POTENTIAL 
(mV) 
F 1 
9 
1:2 -6.78 
F 2 1:4 -18.2 
F 3 1:6 2.51 
F 4 
10 
1:2 -7.99 
F 5 1:4 -9.30 
F 6 1:6 -13.4 
F 7 
8 
1:2 -10.4 
F 8 1:4 -12.4 
F 9 1:6 -14.9 
 
 
 
TABLE 6h. ZETA POTENTIAL OF CEFAZOLIN LOADED BOVINE SERUM 
ALBUMIN NANOPARTICLES FORMULATED AT 500rpm. 
FORMULATION 
CODE pH 
DRUG : 
POLYMER 
RATIO 
ZETA 
POTENTIAL 
(mV) 
F 10 
9 
1:2 -8.96 
F 11 1:4 -11.7 
F 12 1:6 -7.5 
F 13 
10 
1:2 -13.7 
F 14 1:4 -6.36 
F 15 1:6 -10.2 
F 16 
8 
1:2 -15 
F 17 1:4 -13.3 
F 18 1:6 -16.5 
 
 
 
TABLE 7a. COMPARATIVE INVITRO DRUG RELEASE STUDY OF 
CEFAZOLIN LOADED BOVINE SERUM ALBUMIN NANOPARTICLE 
FORMULATIONS F1, F2, F3. 
TIME IN 
HOURS 
CUMULATIVE  % DRUG RELEASE   ±  SD 
F1 F2 F3 
0.5 14.72 ± 0.395 13.33 ±0.395 14.11 ± 0.522 
1 27.65 ± 1.304 29.15 ± 0.202 27.08 ± 0.516 
1.5 32.94 ±1.086 34.20 ± 0.188 33.19 ± 1.208 
2 37.93 ± 0.582 39.08 ± 0.202 38.18 ± 0.432 
3 42.18 ± 0.791 43.49 ± 0.209 42.02 ± 0.551 
4 46.23 ± 1.001 47.17 ± 0.359 45.52 ± 0.564 
5 49.39 ± 0.436 50.06 ± 0.519 48.38 ± 0.477 
6 50.92 ± 1.031 52.03 ± 0.532 50.72 ± 0.660 
7 53.72 ± 0.801 54.29 ± 0.701 52.96 ± 0.831 
8 55.87 ± 0.671 56.59 ± 0.891 54.81 ± 0.680 
9 58.04 ± 0.654 58.77 ± 0.740 56.82 ± 0.620 
10 59.67 ± 0.333 60.84 ± 0.757 58.70 ± 0.567 
11 61.04 ± 0.526 62.51 ± 0.374 60.60 ± 0.580 
12 62.41 ± 0.420 64.05 ± 0.237 62.52 ± 0.655 
n = 3* 
 
 
TABLE 7b. COMPARATIVE INVITRO DRUG RELEASE STUDY OF 
CEFAZOLIN LOADED BOVINE SERUM ALBUMIN NANOPARTICLE 
FORMULATIONS F4, F5, F6. 
TIME IN 
HOURS 
CUMULATIVE  % DRUG RELEASE   ±  SD 
F4 F5 F6 
0.5 13.19 ±0.342 11.51 ± 0.684 15.42 ± 1.294 
1 27.20 ±0.525 23.11 ± 0.577 32.70 ± 0.551 
1.5 34.71 ± 0.701 30.80 ± 1.184 40.90 ± 0.701 
2 39.74 ± 0.620 36.29 ± 1.454 47.06 ± 0.356 
3 43.89 ± 0.556 40.93 ± 1.821 51.67 ± 0.701 
4 47.29 ± 0.449 44.96 ± 1.155 54.69 ± 1.237 
5 49.78 ± 0.578 47.95 ± 0.921 56.64 ± 1.561 
6 52.16 ± 0.591 50.71 ± 0.800 59.17 ± 1.598 
7 54.56 ± 0.604 52.82 ± 0.318 61.73 ± 1.374 
8 56.73 ± 0.431 54.25 ± 0.165 63.90 ± 0.845 
9 58.77 ± 0.439 55.55 ± 0.044 66.24 ± 0.531 
10 60.56 ± 0.511 56.99 ± 0.166 68.45 ± 0.551 
11 62.36 ± 0.641 58.30 ± 0.050 70.27 ± 0.435 
12 63.90 ± 0.975 59.34 ± 0.168 72.24 ± 0.644 
n = 3* 
TABLE 7c. COMPARATIVE INVITRO DRUG RELEASE STUDY OF 
CEFAZOLIN LOADED BOVINE SERUM ALBUMIN NANOPARTICLE 
FORMULATIONS F7, F8, F9. 
TIME IN 
HOURS 
CUMULATIVE  % DRUG RELEASE   ±  SD 
F7 F8 F9 
0.5 6.35 ± 0.712 14.30 ± 0.712 16.68 ± 0.522 
1 14.74 ± 0.727 23.32 ± 1.305 24.91 ± 0.896 
1.5 21.81 ± 0.512 28.91 ± 1.448 31.52 ± 1.123 
2 26.94 ± 0.544 32.82 ± 1.235 35.92 ± 1.275 
3 31.22 ± 0.689 36.26 ± 1.172 39.56 ± 1.056 
4 33.77 ± 0.722 38.92 ± 1.395 43.14 ± 0.755 
5 36.51 ± 0.930 41.48 ± 1.427 46.50 ± 0.835 
6 38.74 ± 1.025 43.81 ± 1.656 49.78 ± 1.032 
7 40.58 ± 0.599 46.18 ± 1.589 52.14 ± 0.719 
8 42.17 ± 0.799 48.44 ± 1.624 54.53 ± 0.402 
9 43.50 ± 0.817 50.59 ± 1.508 56.54 ± 0.411 
10 44.70 ± 1.025 52.77 ± 1.483 58.28 ± 0.511 
11 45.62 ± 1.048 54.83 ±1.425 59.76 ± 0.825 
12 46.69 ± 1.214 56.37 ± 1.138 61.39 ± 1.056 
n = 3* 
 
 
TABLE 7d. COMPARATIVE INVITRO DRUG RELEASE STUDY OF 
CEFAZOLIN LOADED BOVINE SERUM ALBUMIN NANOPARTICLE 
FORMULATIONS F10, F11, F12. 
TIME IN 
HOURS 
CUMULATIVE  % DRUG RELEASE   ±  SD 
F10 F11 F12 
0.5 11.93 ± 0.342 19.89  ± 1.567 15.42  ± 2.061 
1 22.84  ± 0.789 33.52  ± 1.421 28.09  ± 1.234 
1.5 31.08  ± 0.729 42.98  ± 1.293 36.46  ± 1.020 
2 36.16  ± 1.022 49.33  ± 1.111 43.79  ± 0.765 
3 40.23  ± 0.886 53.85  ± 1.309 47.02  ± 0.864 
4 43.13  ± 0.770 57.90  ± 1.522 49.93  ± 1.092 
5 45.66  ± 0.415 61.46  ± 1.713 52.62  ± 1.462 
6 47.67  ± 0.599 64.80  ± 1.595 54.64  ± 1.497 
7 49.28  ± 0.471 67.63  ± 2.127 56.54  ± 1.697 
8 50.77  ± 0.551 70.07  ± 1.997 58.18  ± 1.735 
9 51.99  ± 0.741 72.26  ± 1.876 59.69  ± 1.945 
10 52.93  ± 0.806 74.05  ± 1.420 60.94  ± 1.831 
11 54.15  ± 1.034 75.29  ± 1.497 62.59  ± 1.870 
12 55.10  ± 1.197 76.52  ± 1.662 64.26  ± 1.909 
n = 3* 
TABLE 7e. COMPARATIVE INVITRO DRUG RELEASE STUDY OF 
CEFAZOLIN LOADED BOVINE SERUM ALBUMIN NANOPARTICLES 
FORMULATIONS F13, F14, F15. 
TIME IN 
HOURS 
CUMULATIVE  % DRUG RELEASE   ±  SD 
F13 F`14 F15 
0.5 23.10  ± 1.044 21.28  ± 0.712 24.22  ± 1.099 
1 33.17  ± 1.125 31.87  ± 0.727 35.43  ± 1.405 
1.5 42.50  ± 1.592 40.19  ± 0.217 41.60  ± 1.483 
2 49.11  ± 0.993 46.60  ± 1.418 46.65  ± 2.174 
3 54.18  ± 0.614 50.64  ± 1.267 50.69  ± 2.281 
4 58.38  ± 0.645 53.92  ± 1.144 53.96  ± 1.968 
5 62.23  ± 0.658 56.54  ± 0.986 56.86  ± 1.367 
6 65.03  ± 0.323 59.07  ± 0.847 59.39  ± 1.140 
7 67.44  ± 0.153 61.62  ± 1.122 61.95  ± 1.304 
8 70.01  ± 0.327 63.93  ± 1.078 64.40  ± 0.819 
9 72.34  ± 0.071 65.71  ± 0.547 66.19  ± 0.832 
10 74.41  ± 0.270 67.63  ± 0.733 67.42  ± 0.516 
11 76.35  ± 0.605 69.43  ± 0.746 68.93  ± 0.176 
12 78.02  ± 0.796 70.40  ± 0.943 70.58  ± 0.202 
n = 3* 
 
 
TABLE 7f. COMPARATIVE INVITRO DRUG RELEASE STUDY OF 
CEFAZOLIN LOADED BOVINE SERUM ALBUMIN NANOPARTICLES 
FORMULATIONS F16, F17, F18. 
TIME IN 
HOURS 
CUMULATIVE  % DRUG RELEASE   ±  SD 
F16 F17 F18 
0.5 19.75  ± 1.382 13.89  ± 0.860 16.26  ± 1.044 
1 30.71  ± 1.917 20.93  ± 0.882 29.79  ± 0.543 
1.5 38.03  ± 2.001 24.80  ± 0.903 35.82  ± 0.893 
2 42.99  ± 2.677 27.21  ± 1.090 39.76  ± 0.762 
3 46.12  ± 2.203 29.25  ± 0.949 42.80  ± 0.761 
4 48.85  ± 1.912 31.05  ± 0.689 45.19  ± 0.987 
5 50.81  ± 1.614 32.45  ± 0.807 47.47  ± 1.133 
6 52.92  ± 1.133 34.15  ± 1.021 49.24  ± 0.609 
7 54.92  ± 0.702 35.88  ± 0.982 50.74  ± 0.622 
8 56.52  ± 0.479 36.93  ± 1.332 52.53  ± 0.532 
9 57.99  ± 0.096 37.85  ± 1.078 53.49  ± 0.451 
10 59.75  ± 0.209 39.33  ± 0.989 55.02  ± 0.459 
11 60.96  ± 0.120 40.69  ± 0.814 56.27  ± 0.345 
12 62.17  ± 0.421 41.78  ± 0.437 57.39  ± 0.688 
n = 3*
TABLE 8a.  INVITRO  RELEASE KINETICS OF CEFAZOLIN LOADED BOVINE SERUM ALBUMIN  NANOPARTICLES. 
Formulation 
Code 
Zero order First order Higuchi model 
Korsmeyer 
peppas Hixon-Crowell 
 
R2 
 
K0 
(h-1) 
 
R2 
 
K1 
(h-1) 
 
R2 
 
KH 
(h-1/2) 
 
R2 
 n 
 
R2 
 
KHC 
(h-1/3) 
F1 0.787 4.009 0.891 -0.03 0.947 15.21 0.935 0.392 0.859 -0.088 
F2 0.78 4.089 0.89 -0.031 0.934 15.54 0.901 0.405 0.857 -0.091 
F3 0.786 3.965 0.89 -0.029 0.943 15.04 0.926 0.395 0.858 -0.087 
F4 0.776 4.097 0.885 -0.031 0.929 15.63 0.903 0.412 0.852 -0.091 
F5 0.777 3.967 0.868 -0.028 0.924 15.42 0.911 0.445 0.84 -0.085 
F6 0.747 4.484 0.887 -0.038 0.907 16.88 0.88 0.392 0.845 -0.108 
F7 0.808 3.302 0.868 -0.02 0.93 13.21 0.896 0.537 0.849 -0.064 
F8 0.823 3.599 0.907 -0.024 0.971 13.6 0.964 0.382 0.882 -0.075 
F9 0.819 3.977 0.913 -0.029 0.973 15.08 0.976 0.38 0.885 -0.087 
 
 
TABLE 8b. INVITRO  RELEASE KINETICS OF CEFAZOLIN LOADED BOVINE SERUM ALBUMIN  NANOPARTICLES. 
Formulation 
Code 
Zero order First order Higuchi model 
Korsmeyer 
peppas Hixon-Crowell 
 
R2 
 
K0 
(h-1) 
 
R2 
 
K1 
(h-1) 
 
R2 
 
KH 
(h-1/2) 
 
R2 
 n 
 
R2 
 
KHC 
(h-1/3) 
F10  0.739  3.534  0.826  ‐0.024  0.898  13.5  0.894  0.409  0.798  ‐0.073 
F11  0.764  4.854  0.912  ‐0.045  0.935  18.26  0.935  0.373  0.869  ‐0.124 
F12  0.733  3.984  0.846  ‐0.03  0.903  14.98  0.902  0.38  0.811  ‐0.089 
F13  0.775  4.874  0.925  ‐0.047  0.953  18.19  0.964  0.354  0.883  ‐0.126 
F14  0.751  4.307  0.886  ‐0.036  0.939  15.88  0.95  0.339  0.845  ‐0.103 
F15  0.737  4.154  0.88  ‐0.035  0.951  14.93  0.965  0.303  0.837  ‐0.1 
F16  0.712  3.638  0.83  ‐0.027  0.918  13.11  0.931  0.312  0.793  ‐0.081 
F17  0.746  2.428  0.815  ‐0.014  0.954  8.699  0.959  0.302  0.793  ‐0.046 
F18  0.699  3.358  0.804  ‐0.023  0.896  12.15  0.892  0.325  0.771  ‐0.071 
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FIGURE 5. DETERMINATION OF ABSORPTION MAXIMUM (λmax) OF 
CEFAZOLIN (PBS pH 7.4) 
 
 
 
 
 
 
  
 
FIGURE 6.CALIBRATION CURVE OF CEFAZOLIN  (PBS pH 7.4) 
 
 
  
FIGURE 7(a).IR-SPECTRUM OF CEFAZOLIN 
 FIGURE 7(b).IR-SPECTRUM OF  BOVINE SERUM ALBUMIN 
 FIGURE 7(c). IR-SPECTRUM OF  PHYSICAL MIXTURE 
  
FIGURE 7(d). IR-SPECTRUM OF  BEST FORMULATION ( F7). 
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FIGURE 10(b) .PARTICLE SIZE DISTRIBUTION CURVE OF F1 & F2 
  
 
FIGURE 10(c) .PARTICLE SIZE DISTRIBUTION CURVE OF F13& F4 
  
 
FIGURE 10(d) .PARTICLE SIZE DISTRIBUTION CURVE OF F5 & F6 
 
  
 
FIGURE 10(e).PARTICLE SIZE DISTRIBUTION CURVE OF F7 & F8 
 
  
 
FIGURE 10(f).PARTICLE SIZE DISTRIBUTION CURVE OF F9 & F10 
  
 
FIGURE 10(g).PARTICLE SIZE DISTRIBUTION CURVE OF F11 & F12 
  
 
FIGURE 10(h).PARTICLE SIZE DISTRIBUTION CURVE OF F13 & F14 
 
  
 
FIGURE 10(i).PARTICLE SIZE DISTRIBUTION CURVE OF F1 5& F16 
 
  
 
FIGURE 10(j).PARTICLE SIZE DISTRIBUTION CURVE OF F17 & F18 
 
  
 
 
FIGURE 11(a).ZETAPOTENTIAL OF FORMULATION F1& F2 
 
  
 
FIGURE 11(b).ZETAPOTENTIAL OF FORMULATION F3& F4 
 
 
  
 
FIGURE 11(c).ZETAPOTENTIAL OF FORMULATION F5& F6 
 
  
 
FIGURE 11(d).ZETAPOTENTIAL OF FORMULATION F7& F8 
 
  
 
 
FIGURE 11(e).ZETAPOTENTIAL OF FORMULATION F9& F10 
 
FIGURE 11(f).ZETAPOTEN
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FORMULATION F11& F12 
 
 
  
 
FIGURE 11(g).ZETAPOTENTIAL OF FORMULATION F13& F14 
 
 
  
 
FIGURE 11(h).ZETAPOTENTIAL OF FORMULATION F15& F16 
 
  
 
FIGURE 11(i).ZETAPOTENTIAL OF FORMULATION F17& F18 
 
FIGURE 12(a). PDI & ZETA POTENTIAL OF F1 – F9 
 
FIGURE 12(b). PDI & ZETA POTENTIAL OF F10 – F18 
FIGURE 13(a).COMPARATIVE INVITRO DRUG RELEASE STUDY OF 
CEFAZOLIN LOADED BOVINE SERUM ALBUMIN NANOPARTICLES 
PREPARED AT 1000 RPM IN pH 9. 
 
FIGURE 13(b).COMPARATIVE INVITRO DRUG RELEASE STUDY OF 
CEFAZOLIN LOADED BOVINE SERUM ALBUMIN NANOPARTICLES 
PREPARED AT 1000 RPM IN pH 10. 
FIGURE 13(c).COMPARATIVE INVITRO DRUG RELEASE STUDY OF 
CEFAZOLIN LOADED BOVINE SERUM ALBUMIN NANOPARTICLES 
PREPARED AT 1000 RPM IN pH 8. 
FIGURE 13(d).COMPARATIVE INVITRO DRUG RELEASE STUDY OF 
CEFAZOLIN LOADED BOVINE SERUM ALBUMIN NANOPARTICLES 
PREPARED AT 500 RPM IN pH 9. 
FIGURE 13(e).COMPARATIVE INVITRO DRUG RELEASE STUDY OF 
CEFAZOLIN LOADED BOVINE SERUM ALBUMIN NANOPARTICLES 
PREPARED AT 500 RPM IN pH 10. 
 
FIGURE 13(f).COMPARATIVE INVITRO DRUG RELEASE STUDY OF 
CEFAZOLIN LOADED BOVINE SERUM ALBUMIN NANOPARTICLES 
PREPARED AT 1000 RPM IN pH 8. 
FIGURE 14(a). COMPARATIVE ZERO ORDER RELEASE KINETICS OF 
CEFAZOLIN LOADED BSA NANOPARTICLES, 1000 RPM, pH 9. 
 
FIGURE 14(b). COMPARATIVE ZERO ORDER RELEASE KINETICS OF 
CEFAZOLIN LOADED BSA NANOPARTICLES, 1000 RPM, pH 10. 
 FIGURE 14(c). COMPARATIVE ZERO ORDER RELEASE KINETICS OF 
CEFAZOLIN LOADED BSA NANOPARTICLES, 1000 RPM, pH 8. 
 
FIGURE 14(d ). COMPARATIVE ZERO ORDER RELEASE KINETICS OF 
CEFAZOLIN LOADED BSA NANOPARTICLES, 500 RPM, pH 9. 
 FIGURE 14(e). COMPARATIVE ZERO ORDER RELEASE KINETICS OF 
CEFAZOLIN LOADED BSA NANOPARTICLES, 500 RPM, pH 10. 
 
FIGURE 14(f ). COMPARATIVE ZERO ORDER RELEASE KINETICS OF 
CEFAZOLIN LOADED BSA NANOPARTICLES, 500 RPM, pH 8. 
 FIGURE 15(a). COMPARATIVE KORSEMEYER PEPPAS MODEL 
RELEASE KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 
1000 RPM, pH 9. 
 
FIGURE 15(b).COMPARATIVE KORSEMEYER PEPPAS MODEL 
RELEASE KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 
1000 RPM, pH 10. 
FIGURE 15(c). COMPARATIVE KORSEMEYER PEPPAS MODEL 
RELEASE KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 
1000 RPM, pH 8. 
 
FIGURE 15(d).COMPARATIVE KORSEMEYER PEPPAS MODEL 
RELEASE KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 
500 RPM, pH 9. 
FIGURE 15(e). COMPARATIVE KORSEMEYER PEPPAS MODEL 
RELEASE KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 
500 RPM, pH 10. 
 
FIGURE 15(f). COMPARATIVE KORSEMEYER PEPPAS MODEL 
RELEASE KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 
500 RPM, pH 8. 
 FIGURE 16(a ). COMPARATIVE INVITRO HIXON CROWELL MODEL 
RELEASE KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 
1000 RPM, pH 9. 
FIGURE 16(b). COMPARATIVE INVITRO HIXON CROWELL MODEL 
RELEASE KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 
1000 RPM, pH 10. 
 FIGURE 16(c ). COMPARATIVE INVITRO HIXON CROWELL MODEL 
RELEASE KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 
1000 RPM, pH 8. 
 
FIGURE 16(d ). COMPARATIVE INVITRO HIXON CROWELL MODEL 
RELEASE KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 
500 RPM, pH 9. 
 FIGURE 16(e ). COMPARATIVE INVITRO HIXON CROWELL MODEL 
RELEASE KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 
500 RPM, pH 10. 
 
FIGURE 16(f ).COMPARATIVE INVITRO HIXON CROWELL MODEL 
RELEASE KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 
500 RPM, pH 8. 
 FIGURE 17(a). COMPARATIVE HIGUCHI MODEL  RELEASE KINETICS 
OF CEFAZOLIN LOADED BSA NANOPARTICLES, 500 RPM, pH 10. 
 
 
FIGURE 17(b ). COMPARATIVE HIGUCHI MODEL  RELEASE KINETICS 
OF CEFAZOLIN LOADED BSA NANOPARTICLES, 500 RPM, pH 8. 
 FIGURE 17(c ). COMPARATIVE HIGUCHI MODEL  RELEASE KINETICS 
OF CEFAZOLIN LOADED BSA NANOPARTICLES, 1000 RPM, pH 9. 
 
 
FIGURE 17(d ).COMPARATIVE HIGUCHI MODEL  RELEASE KINETICS 
OF CEFAZOLIN LOADED BSA NANOPARTICLES, 1000 RPM, pH 10. 
 FIGURE 17(e ). COMPARATIVE HIGUCHI MODEL  RELEASE KINETICS 
OF CEFAZOLIN LOADED BSA NANOPARTICLES, 1000 RPM, pH 8. 
 
FIGURE 17(f ). COMPARATIVE HIGUCHI MODEL  RELEASE KINETICS 
OF CEFAZOLIN LOADED BSA NANOPARTICLES, 500 RPM, pH 9. 
 FIGURE 18(a). COMPARATIVE INVITRO FIRST ORDER  RELEASE 
KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 1000 RPM, 
pH 9. 
 FIGURE 18(b). COMPARATIVE INVITRO FIRST ORDER  RELEASE 
KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 1000 RPM, 
pH 10. 
 FIGURE 18(c ).COMPARATIVE INVITRO FIRST ORDER  RELEASE 
KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 1000 RPM, 
pH 8. 
 FIGURE 18(d ). COMPARATIVE INVITRO FIRST ORDER  RELEASE 
KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 500 RPM, 
pH 9. 
 FIGURE 18(e). COMPARATIVE INVITRO FIRST ORDER  RELEASE 
KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES,500 RPM, pH 
10. 
 FIGURE 18(f). COMPARATIVE INVITRO FIRST ORDER  RELEASE 
KINETICS OF CEFAZOLIN LOADED BSA NANOPARTICLES, 500 RPM, 
pH 8 
 FIGURE 19. SCANNING ELECTRON MICROSCOPY OF CEFAZOLIN 
LOADED BSA NANOPARTICLES WITH CRYOPROTECTANT. 
 
 
 
FIGURE 20.  MICROBIOLOGICAL ASSAY OF CEFAZOLIN LOADED BSA 
NANOPARTICLES  
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CHAPTER - X 
SUMMARY AND CONCLUSION 
Summary: 
 In the present an attempt was made to develop nanoparticles of cefazolin with 
controlled particle size in order to increase its circulation half life thereby 
sustain its therapeutic activity using BSA as polymer. 
 IR spectroscopy studies confirmed there was an interaction between drug and 
polymer. 
 The cefazolin loaded nanoparticles were successfully prepared by desolvation 
technique using various concentration of BSA (1%, 2%, 3%) in different pH 
(8, 9, 10) at two different rpm (1000, 500). 
 The drug content analysis showed minimum variations, suggesting uniform 
distribution of drug. 
 The entrapment efficiency of all the formulations were decreased with 
increasing pH and not affected by polymer concentration. 
 Particle size analyzer (Malvern) used to explore the particle size of cefazolin 
loaded BSA nanoparticles showed a particle size in the range of 46.9nm-
345.3nm. 
 The polydispersity index of nanoparticle formulations F1-F18 was less than 
0.5 except F16(0.608), which indicated a relatively homogenous dispersion of 
particles. 
 Zeta potential of cefazolin BSA nanoparticles showed a negative surface 
charge due to the presence of carboxylic groups in the polymer. 
 The invitro drug release studies displayed a biphasic drug release pattern with 
a burst release within 0.5 hrs followed by sustained release for 12hours. 
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 Invitro drug release kinetics showed sustained release and Fickian diffusion 
mechanism which indicated that the drug release was diffusion controlled. 
 On the basis of particle size and release data formulation F7 (prepared using 
1% BSA + pH 8 + 1000 rpm) showed a good sustained release profile with 
high entrapment efficiency. 
 SEM images confirmed the morphology of the drug loaded nanoparticles (F7) 
was sphere and had particle size less than 100nm. 
 The infra red spectrum of nanoparticle formulation shows changes in amino 
group functional peak, it indicates the nanoparticle crosslinked by 
glutaraldehyde. 
 Microbiological assay revealed that the nanoparticle formulation retained their 
antibacterial activity and also showed zone of inhibition 36mm after 24 hours. 
Conclusion: 
 Hence, Cefazolin loaded albumin nanoparticles can be successfully prepared 
by coacervation following crosslinking with glutaraldehyde. The characterizations of 
the resulting nanoparticles were dependent on the polymer concentration, pH and the 
rpmof thestirrer during the desolvating process. And number of variables which might 
affect the final nanoparticle size was investigated to optimize the formulation.The 
preparation process of BSA nanoparticles was optimized by varying various 
parameter pH(8-10),polymer concentration (1%-3%) and rpm of the stirrer 
(1000,500), wherein pH 8, 1% polymer concentration and 1000rpm were found to be 
most favorable. The invitro release studies indicated there was an initial burst release 
of the drug in 0.5 hours followed by sustained release for 12 hours. According to the 
literature, the results demonstrated that produced nanoparticles have sufficient 
properties as a carrier for drug delivery systems.  
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